

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number  
WO 02/46171 A2

(51) International Patent Classification<sup>7</sup>: C07D 239/42,  
401/12, 405/12, 413/12, 403/12, A61K 31/505, A61P  
29/00

(74) Agents: INSOGNA, Anthony, M. et al.; Pennie & Ed-  
monds LLP, 1155 Avenue of the Americas, New York, NY  
10036 (US).

(21) International Application Number: PCT/US01/46403

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/251,816 6 December 2000 (06.12.2000) US

(71) Applicant: SIGNAL PHARMACEUTICALS, INC.  
[US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US).

(72) Inventors: KOIS, Adam; 11363 Redbud Court, San  
Diego, CA 92127 (US). MACFARLANE, Karen, J.;  
11435 Belshire Lane, San Diego, CA 92126 (US).  
SATO, Yoshitaka; 11460 Larmier Circle, San Diego,  
CA 92131 (US). BHAGWAT, Shripad, S.; 5015 Ashley  
Falls Court, San Diego, CA 92130 (US). PARNES, Jason,  
S.; 12511 El Camino Real #C, San Diego, CA 92139 (US).  
PALANKI, Moorthy, S., S.; 602 Crest Drive, Encinitas,  
CA 92024 (US). ERDMAN, Paul, E.; 8225 Jade Coast  
#93, San Diego, CA 92126 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).


**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/46171 A2

(54) Title: ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED  
THERE TO



(57) Abstract: Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: (A) wherein R<sub>1</sub> and R<sub>6</sub> are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods or treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND  
COMPOSITIONS AND METHODS RELATED THERETO

5 This application claims the benefit of U.S. Provisional Application No.  
60/251,816, filed December 6, 2000, incorporated by reference herein in its entirety.

1. FIELD OF THE INVENTION

10 This invention is generally directed to anilinopyrimidine derivatives that  
have utility as I $\kappa$ B kinase (IKK) inhibitors, and particularly as IKK-2 inhibitors, as well to  
related compositions and methods.

2. BACKGROUND OF THE INVENTION

15 NF- $\kappa$ B is a heterodimeric transcription transcription factor regulating the  
expression of multiple inflammatory genes. The expression of more than 70 known proteins  
is transcriptionally regulated by the binding of NF- $\kappa$ B to specific sequence elements in the  
promoter region of these genes (Baeuerle and Baichwal, *Advances in Immunology* 65:111 -  
137, 1997) NF- $\kappa$ B has been implicated in many pathophysiologic processes including  
angiogenesis (Koch et al., *Nature* 376:517-519, 1995), atherosclerosis (Brand et al., *J Clin*  
20 *Inv.* 97:1715-1722, 1996), endotoxic shock and sepsis (Bohrer et al., *J. Clin. Inv.* 100:972-  
985, 1997), inflammatory bowel disease (Panes et al., *Am J Physiol.* 269:H1955-H1964,  
1995), ischemia/reperfusion injury (Zwacka et al., *Nature Medicine* 4:698-704, 1998), and  
allergic lung inflammation (Gosset et al., *Int Arch Allergy Immunol.* 106:69-77, 1995).  
Because of the central role of NF- $\kappa$ B in inflammatory disease, inhibition of NF- $\kappa$ B by  
25 targeting regulatory proteins in the NF- $\kappa$ B activation pathway represents an attractive  
strategy for generating anti-inflammatory therapeutics.

The I $\kappa$ B kinases (IKKs), are key regulatory signaling molecules coordinating  
the activation of NF- $\kappa$ B. IKK-1 and IKK-2 are structurally unique kinases containing an  
N-terminal kinase domain with a dual serine activation loop, a leucine zipper domain, and a  
30 C-terminal helix-loop-helix domain and serine cluster. IKK enzymes show relatively low  
sequence homologies with other kinases, and early profiles with known kinase inhibitors  
have not identified compounds with striking potency. Kinetic analysis shows that IKK-2  
binds to and phosphorylates I $\kappa$ B $\alpha$ , I $\kappa$ B $\beta$ , and I $\kappa$ B $\epsilon$  with high and relatively equal affinities  
(Heilker *et.al.* 1999). Recombinant IKK-2 phosphorylates I $\kappa$ B $\alpha$  peptide 26-42 with near  
35 equal affinity to full length I $\kappa$ B $\alpha$ , however the native IKK enzyme complex phosphorylates

full length I $\kappa$ B $\alpha$  25,000 fold more efficiently, suggesting important regulatory sequences in the C-terminal region of I $\kappa$ B $\alpha$ , or additional regulatory proteins in the IKK enzyme complex that accelerate the rate of catalysis (Burke et al., *Journal of Biological Chemistry* 274:36146-36152, 1999). Phosphorylation of I $\kappa$ B $\alpha$  occurs via a random sequential kinetic mechanism, meaning either ATP or I $\kappa$ B $\alpha$  may bind first to IKK-2, t that both must be bound before phosphorylation of I $\kappa$ B $\alpha$  can take place (Peet and Li, *Journal of Biological Chemistry* 274:32655-32661, 1999). IKK-2 binds ATP with uniquely high affinity ( $K_i$  = 130 nM) compared to other serine-threonine kinases such as p38 and JNK perhaps indicating a unique ATP binding pocket that reflects the relatively poor activity to many broad specificity kinase inhibitors when tested against IKK-2. To date, no crystal structure of IKK-2 has been reported. However homology modeling has identified 3 structural domains including an N-terminal kinase domain with an activation loop, a leucine zipper domain that likely mediates the formation of IKK-1 and IKK-2 homo/heterodimers, and a C-terminal helix-loop-helix with serine rich tail. Activation of IKK-2 is critically dependent upon phosphorylation of serine 177 and 181 in the activation or T loop. Alanine mutations abolish activity, while glutamate mutations result in a constitutively active enzyme (Mercurio et al. *Science* 278:860-866, 1997; Delhase et al., *Science* 284:30 313, 1999).

IKK-1 and IKK-2 occur both as heterodimers and IKK-2 homodimers, and are associated with a 700-900 kDa cytoplasmic enzyme complex called the "IKK Signalsome" (Mercurio et al., *Science* 278:860-866, 1997). Another component, IKKAP-1 or NEMO/IKK $\gamma$  has no apparent catalytic function but will associate directly with IKK-2 and is necessary for full activation of NF- $\kappa$ B (Mercurio et al., *Mol Cell Biol.* 19:1526-1538, 1999). Many immune and inflammatory mediators including TNF $\alpha$ , lipopolysaccharide (LPS), IL-1, anti-CD28, CD40L, FasL, viral infection, and oxidative stress have been shown to lead to NF- $\kappa$ B activation. Although the receptor complexes that transduce these diverse stimuli appear very different in their protein components, it is understood that each of these stimulation events leads to activation of the IKKs and NF- $\kappa$ B.

The IKK complex appears to be the central integrator of diverse inflammatory signals leading to the phosphorylation of I $\kappa$ B. IKKs are activated at dual serine residues by upstream kinases including NF- $\kappa$ B inducing kinase, NIK (Malinin et al., *Nature* 385:540-544, 1997), and MEKK-1 (Yujiri et al., *Science* 282:1911-1914, 1998). The differential activities of NIK and MEKK-1 remain unclear although initial data indicates these kinases may preferentially activate IKK-1 and IKK-2, respectively. Activated IKK phosphorylates a cytoplasmic inhibitor protein, I $\kappa$ B which binds NF- $\kappa$ B, thereby masking a nuclear localization signal present in Rel proteins (Cramer et al., *Structure* 7:R1-R6, 1999).

IKK phosphorylation of I $\kappa$ B on serines 32 and 36 forms a structural motif recognized by the E3 ligase,  $\beta$ TRcP (Yaron et al., *Nature* 396:590-594, 1998). Docking of  $\beta$ TRcP results in the formation of a ligase complex which polyubiquitinates I $\kappa$ B thus targeting it for degradation by the 26S proteasome. Free NF- $\kappa$ B is then identified by nuclear transport proteins which translocate it to the nucleus where it can associate with sequence specific regulatory elements on gene promoters.

Although both kinases can phosphorylate I $\kappa$ B *in vitro*, early studies using genetic mutants indicated that IKK-2, but not IKK-1, was essential for activation of NF- $\kappa$ B by pro-inflammatory stimuli such as IL-1 $\beta$  and TNF $\alpha$ . Furthermore, only catalytically inactive mutants of IKK-2 blocked the expression of NF- $\kappa$ B regulated genes such as monocyte chemotactic protein (MCP-1) and intercellular adhesion molecule (ICAM-1) (Mercurio et al., *Science* 278:860-866, 1997). Studies of knockout animals for IKK-1 and IKK-2 substantiate these initial findings (Hu et al., *Science* 284:316-320, 1999; Li et al., *Genes & Development* 13:1322-1328, 1999; Li et al., *Science* 284:321-324, 1999; Takeda et al., *Science* 84:313-316, 1999; Tanaka et al., *Immunity* 10:421-429, 1999). IKK-1<sup>-/-</sup> animals were born alive but died within hours. Pups showed abnormalities of the skin due to defective proliferation and differentiation, but showed no gross deficiency in cytokine induced activation of NF- $\kappa$ B. In contrast, IKK-2<sup>-/-</sup> embryos died at day 14-16 of pregnancy from liver degeneration and apoptosis that bore a striking resemblance to that observed in Rel A knock-out animals (Beg et al., *Nature* 376:167-170, 1995). Furthermore, embryonic fibroblasts from IKK-2<sup>-/-</sup> animals exhibited markedly reduced NF- $\kappa$ B activation following cytokine stimulation, while IKK-1<sup>-/-</sup> did not.

Accordingly, cell and animal experiments indicate that IKK-2 is a central regulator of the pro-inflammatory role of NF- $\kappa$ B. IKK-2 is activated in response to multiple inflammatory stimuli and signaling pathways, many of which play an important role in respiratory disease including IL-1 $\beta$ , LPS, TNF $\alpha$ , CD3/CD28 (antigen presentation), CD40L, viral infection, and oxidative stress. The ubiquitous expression of NF- $\kappa$ B, along with its response to multiple stimuli means that almost all cell types present in the lung are potential target for anti-NF- $\kappa$ B/IKK-2 therapy. This includes alveolar epithelium, mast cells, fibroblasts, vascular endothelium, and infiltrating leukocytes; neutrophils, macrophages, lymphocytes, eosinophils and basophils. By inhibiting the expression of genes such as cyclooxygenase-2 and 12-lipoxygenase (synthesis of inflammatory mediators), TAP-1 peptide transporter (antigen processing), MHC class I H-2K and class II invariant chains (antigen presentation), E-selectin and vascular cell adhesion molecule (leukocyte recruitment), interleukins- 1, 2, 6, 8 (cytokines), RANTES, eotaxin, GM-CSF (chemokines),



and superoxide dismutase and NADPH quinone oxidoreductase (reactive oxygen species), inhibitors of IKK-2 are believed to display broad anti-inflammatory activity.

International Publication No. WO 98/18782 to Celltech Therapeutics Limited discloses 4-pyridyl pyrimidine compounds which are allegedly useful in the prophylaxis and treatment of immune diseases, allergic diseases involving mast cells or eosinophils, and diseases involving inappropriate platelet activation.


Accordingly, there is a need in the art for selective inhibitors of IKK, particularly IKK2 inhibitors. In addition, there is a need for pharmaceutical compositions comprising one or more inhibitors, as well as to methods for treating conditions in animals which are responsive to such inhibitors. The present invention fulfills these needs, and provides further related advantages.

Citation of identification of any reference in Section 2 of this application shall not be construed as an admission that such reference is prior art to the present invention.

### 3. SUMMARY OF THE INVENTION

In brief, the present invention is directed to compounds having activity as inhibitors, preferably selective inhibitors, of  $\kappa$ B kinase (IKK), particularly IKK-2, and to compositions and methods related thereto.

The compounds of the present invention are "anilinopyrimidine derivatives" having the following structure (I):



wherein R<sub>1</sub> through R<sub>6</sub> are as defined below, and including isomers, prodrugs and pharmaceutically acceptable salts thereof.

In general, the present invention is directed to methods for treating or preventing a condition responsive to IKK-2 inhibition, comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

The present invention is also directed to methods for treating or preventing an inflammatory or autoimmune condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

The present invention is also directed to methods for treating or preventing a cardiovascular, metabolic or ischemic condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

5 The present invention is also directed to methods for treating or preventing an infectious disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

The present invention is also directed to methods for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.


10 The present invention is also directed to methods for treating or preventing stroke, epilepsy, Alzheimer's disease, or Parkinson's disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

These and other aspects of this invention will be evident upon reference to the following detailed description and illustrative examples, which are intended to  
15 exemplify non-limiting embodiments of the invention. Certain patent and other documents are cited herein to more specifically set forth various aspects of this invention. Each of these documents are hereby incorporated by reference in their entirety.

#### 4. DETAILED DESCRIPTION OF THE INVENTION

20 The present invention is directed to anilinopyrimidine derivatives having activity as inhibitors, preferably selective inhibitors, of  $\text{I}\kappa\text{B}$  kinase (IKK), particularly IKK-2, and to compositions and methods related thereto.

The anilinopyrimidine derivatives have the following structure (I):



30 including isomers, prodrugs and pharmaceutically acceptable salts thereof,  
wherein:

$\text{R}_1$  is aryl or heteroaryl optionally substituted with one to four substituents independently selected from  $\text{R}_7$ ;

$\text{R}_2$  is hydrogen;

35  $\text{R}_3$  is hydrogen or lower alkyl;

$R_4$  represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;

$R_5$  and  $R_6$  are the same or different and independently  $-R_8$ ,  $-(CH_2)_aC(=O)R_9$ ,  $-(CH_2)_aC(=O)OR_9$ ,  $-(CH_2)_aC(=O)NR_9R_{10}$ ,  $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$ ,  $-(CH_2)_aNR_9C(=O)R_{10}$ ,  $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$ ,  $-(CH_2)_aNR_9R_{10}$ ,  $-(CH_2)_aOR_9$ ,  $-(CH_2)_aSO_cR_9$  or  $-(CH_2)_aSO_2NR_9R_{10}$ ;

or  $R_5$  and  $R_6$  taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

$R_7$  is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-OC(=O)R_8$ ,  $-C(=O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_cR_8$ ,  $-SO_cNR_8R_9$ ,  $-NR_8SO_cR_9$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

$a$  and  $b$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

$c$  is at each occurrence 0, 1 or 2.

In one embodiment of the invention, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is a substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not pyridyl. When  $R_1$  is substituted, it is substituted with one or more substituents defined below. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.

In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl,

benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.


In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl. When  $R_1$  is substituted, it is substituted with one or more substituents defined below. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.

In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl, preferably phenyl. When  $R_1$  is a substituted aryl, the aryl is substituted with one or more substituents defined below. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.


In another embodiment of the invention, in anilinopyrimidine derivatives of structure (I),  $R_5$  and  $R_6$ , taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle, preferably piperazinyl, piperidinyl or morpholinyl.

When  $R_5$  and  $R_6$ , taken together with the nitrogen atom to which they are attached form substituted piperazinyl, piperadinyl or morpholinyl, the piperazinyl, piperadinyl or morpholinyl is substituted with one or more substituents defined below. Preferably, when substituted, the substituent is alkyl, amino, alkylamino, alkylether, acyl, pyrrolidinyl or piperidinyl.


In one embodiment of the invention, in the anilinopyrimidine derivatives of structure (I),  $R_3$  is hydrogen and  $R_4$  is not present, and the compounds of this invention have the following structure (II):



In a more specific embodiment of the invention, in the anilinopyrimidine derivatives of structure (II),  $R_1$  is phenyl optionally substituted with  $R_7$ , and having the following structure (III):



10 In still a further embodiment of the invention, in the anilinopyrimidine derivatives of structure (III),  $R_7$  is at the para position relative to the pyrimidine, as represented by the following structure (IV):



20 As used herein, the terms used above having following meaning:

“Alkyl” means a straight chain or branched, saturated or unsaturated alkyl, cyclic or non-cyclic hydrocarbon having from 1 to 10 carbon atoms, while “lower alkyl” has the same meaning but only has from 1 to 6 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (also referred to as an “alkenyl” or “alkynyl”, respectively). Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butylnyl, 2-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-methyl-1 butynyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like. Cycloalkyls are also referred to herein as “carbocyclic” rings systems, and include bi- and tri-cyclic ring systems having from 8 to 14 carbon atoms such

as a cycloalkyl (such as cyclopentane or cyclohexane) fused to one or more aromatic (such as phenyl) or non-aromatic (such as cyclohexane) carbocyclic rings.

“Halogen” means fluorine, chlorine, bromine or iodine.

“Keto” means a carbonyl group (*i.e.*, =O).

5 “Aryl” means an aromatic carbocyclic moiety such as-phenyl or naphthyl.

“Arylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with an aryl moiety, such as benzyl,  $-(CH_2)_2$ phenyl,  $-(CH_2)_3$ phenyl,  $-CH(phenyl)_2$ , and the like.

10 “Heteroaryl” means an aromatic heterocycle ring of 5- to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and bicyclic ring systems. Representative heteroaryls are pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinoliny, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 15 triazinyl, cinnoliny, phthalazinyl, and quinazolinyl.

“Heteroarylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heteroaryl moiety, such as  $-CH_2$ pyridinyl,  $-CH_2$ pyrimidinyl, and the like.

“Heterocycle” means a heterocyclic ring containing from 5 to 10 ring atoms

20 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any 25 heteroatom or carbon atom. Heterocycles include heteroaryls as defined above. Thus, in addition to the heteroaryls listed above, heterocycles also include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, 30 tetrahydrothiopyranyl, and the like.

“Heterocyclealkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heterocycle, such as  $-CH_2$ morpholinyl, and the like.

35 The term “substituted” as used herein means any of the above groups (*i.e.*, aryl, arylalkyl, heterocycle and heterocyclealkyl) wherein at least one hydrogen atom is replaced with a substituent. In the case of a keto substituent (“C(=O)”) two hydrogen atoms

are replaced. Substituents include halogen, hydroxy, alkyl, substituted alkyl (such as haloalkyl, mono- or di-substituted aminoalkyl, alkyloxyalkyl, and the like, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -NR<sub>a</sub>R<sub>b</sub>, -NR<sub>a</sub>C(=O)R<sub>b</sub>, -NR<sub>a</sub>C(=O)NR<sub>a</sub>R<sub>b</sub>, -NR<sub>a</sub>C(=O)OR<sub>b</sub>,  
 5 -NR<sub>a</sub>SO<sub>2</sub>R<sub>b</sub>, -OR<sub>a</sub>, -C(=O)R<sub>a</sub>, -C(=O)OR<sub>a</sub>, -C(=O)NR<sub>a</sub>R<sub>b</sub>, -OC(=O)R<sub>a</sub>, -OC(=O)OR<sub>a</sub>,  
 -OC(=O)NR<sub>a</sub>R<sub>b</sub>, -NR<sub>a</sub>SO<sub>2</sub>R<sub>b</sub>, or a radical of the formula -Y-Z-R<sub>a</sub> where Y is alkanediyl, substitute alkanediyl, or a direct bond, Z is -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sub>b</sub>)-, -C(=O)-, -C(=O)O-, -OC(=O)-, -N(R<sub>b</sub>)C(=O)-, -C(=O)N(R<sub>b</sub>)- or a direct bond, wherein R<sub>a</sub> and R<sub>b</sub> are the same or different and independently hydrogen, amino, alkyl, substituted alkyl (including  
 10 halogenated alkyl), aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl, or wherein R<sub>a</sub> and R<sub>b</sub> taken together with the nitrogen atom to which they are attached form a heterocycle or substituted heterocycle.

“Haloalkyl” means alkyl having one or more hydrogen atoms replaced with  
 15 halogen, such as -CF<sub>3</sub>.

“Hydroxyalkyl” means alkyl having one or more hydrogen atoms replaced with hydroxy, such as -CH<sub>2</sub>OH

“Sulfonylalkyl” means -SO<sub>2</sub>-(alkyl);

“Sulfinylalkyl” means -SO-(alkyl);

20 “Thioalkyl” means -S-(alkyl);

“Carboxyl” means -COOH.

“Alkoxy” means -O-(alkyl), such as methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butyloxy, iso-butyloxy, and the like.

“Patient” means an animal, including, but not limited to, an animal such as a  
 25 cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, and guinea pig, and is more preferably a mammal, and most preferably a human.

“Acyl” means alkyl(C=O)


“ClH” means the hydrochloride salt of compounds depicted by their chemical structure.

30 “Nitrogen-containing non-aromatic heterocycle” means morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, hydantoinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, oxazolidinyl, thiazolidinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and the like.

35


The anilinopyrimidine derivatives can generally be obtained using organic synthesis techniques known to those skilled in the art, as well as by the following general techniques and the procedures set forth in the Examples. To that end, the anilinopyrimidine derivatives can be made according to the following Reaction Schemes 1 through 9:

5 Reaction Scheme 1




Appropriately substituted methylketones may be treated with a dimethylformamide acetal, such as dimethylformamide dimethylacetal or dimethylformamide diethylacetal, to afford the corresponding  $\beta$ -dimethylaminobutenones. Treatment of the aminobutenones with thiourea in the presence of a base such as sodium methoxide, followed by alkylation with an alkyl halide, such as methyl iodide, gives 4-substituted 2-alkylthiopyrimidines. Oxidation of the thioether with organic and inorganic oxidizing agents, such as *m*-chloroperbenzoic acid or oxone, yields the sulfones which, upon condensation with *p*-aminocarbonylanilines, give rise to the formation of the desired anilinopyrimidine derivatives.



Reaction Scheme 2

15 Similarly, the anilinopyrimidine derivatives may be prepared from the 2-chloropyrimidine derivatives. Thus, condensation of the  $\beta$ -dimethylaminobutenones with urea followed by the treatment with chlorinating agent such as phosphorus oxychloride gives 4-substituted 2-chloropyrimidines. Further treatment with substituted anilines affords the desired anilinopyrimidine derivatives.


20 Reaction Scheme 3

35 The anilinopyrimidine derivatives can also be prepared by condensation of the  $\beta$ -dimethylaminobutenones with appropriately substituted guanidines. The requisite

guanidines may be synthesized by the reaction of the aniline with cyanamide in the presence of an acid, or with a pyrazoloamidine.

#### Reaction Scheme 4


5



Cyclization of alkoxycarbonylphenylguanidines with the  $\beta$ -aminoketones gives 4-substituted 2-(4-carboxyphenyl)aminopyrimidines. Condensation of the benzoic acid derivatives with appropriate amines affords the desired amides.

20

#### Reaction Scheme 5




Condensation of the benzoic acids with N-Boc-piperazine followed by deprotection of the tert-butoxycarbonyl group with an acid such as hydrochloric acid yields

35


piperazineamides. Subsequent condensation with carboxylic acid derivatives yields bisacylpiperazines.

#### Reaction Scheme 6




10 Similar reaction with sulfonyl chlorides gives the corresponding sulfonamides.

#### Reaction Scheme 7




20 Acetophenones with p-alkyl- and arylthio groups may be prepared by the reaction of p-chloroacetophenone with alkyl and arylthiols.

#### Reaction Scheme 8



30 Anilinopyrimidine derivatives having the p-alkyl- and arylsulfenyl groups may be prepared by controlled oxidation of the sulfides with an oxidizing agent such as oxone.

Reaction Scheme 9

10 Anilinopyrimidine derivatives having p-alkyl- and arylsulfonyl groups may be prepared by oxidation of the sulfides with an oxidizing agent such as oxone.

The anilinopyrimidine derivatives can be in the form of a pharmaceutically acceptable salt or free base. Acid addition salts of the free base can be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Additional salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate, and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. The term "pharmaceutically acceptable salt" is intended to encompass any and all acceptable salt forms.


Pharmaceutically acceptable salts can be formed by conventional and known techniques, such as by reacting a compound of this invention with a suitable acid as disclosed above. Such salts are typically formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash in the final step of the synthesis. The salt-forming acid may dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the anilinopyrimidine derivative is desired in the free base form, it may be isolated from a basic final wash step, according to known techniques. For example, a typical technique for preparing hydrochloride salt is to dissolve the free base in a suitable solvent, and dry the

solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it.

The anilinopyrimidine derivatives can also exist in various isomeric forms, including configurational, geometric and conformational isomers, as well as existing in various tautomeric forms, particularly those that differ in the point of attachment of a hydrogen atom. As used herein, the term "isomer" is intended to encompass all isomeric forms of a compound, including tautomeric forms of the compound.

As used herein, the term "prodrug" refers to any derivative of the anilinopyrimidine derivatives that are metabolized or otherwise converted into an active form upon introduction into the body of an animal. Prodrugs are well known to those skilled in the art of pharmaceutical chemistry, and provide benefits such as increased adsorption and half-life. Prodrugs of this invention may be formed when, for example, hydroxy groups are esterified or alkylated, or when carboxyl groups are esterified. Those skilled in the art of drug delivery will readily appreciate that the pharmacokinetic properties of anilinopyrimidine derivatives may be controlled by an appropriate choice of moieties to produce prodrug derivatives.

In another embodiment, the present invention provides a method for treating or preventing a condition responsive to IKK-2 inhibition, comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative having the formula of structure (I):



including isomers, prodrugs and pharmaceutically acceptable salts thereof, wherein

R<sub>1</sub> is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R<sub>7</sub>;

R<sub>2</sub> and R<sub>3</sub> are the same or different and are independently hydrogen or lower alkyl;

R<sub>4</sub> represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;

$R_5$  and  $R_6$  are the same or different and independently  $-R_8$ ,  $-(CH_2)_aC(=O)R_9$ ,  
 $-(CH_2)_aC(=O)OR_9$ ,  $-(CH_2)_aC(=O)NR_9R_{10}$ ,  
 $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$ ,  $-(CH_2)_aNR_9C(=O)R_{10}$ ,  
 $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$ ,  $-(CH_2)_aNR_9R_{10}$ ,  $-(CH_2)_aOR_9$ ,  $-(CH_2)_aSO_cR_9$   
 5 or  $-(CH_2)_aSO_2NR_9R_{10}$ ;

or  $R_5$  and  $R_6$  taken together with the nitrogen atom to which they are attached  
 to form a heterocycle or substituted heterocycle;

$R_7$  is at each occurrence independently halogen, hydroxy, cyano, nitro,  
 carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl,  
 10 sulfonylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl,  
 heterocycle, substituted heterocycle, heterocyclealkyl, substituted  
 heterocyclealkyl,  $-C(=O)OR_8$ ,  $-OC(=O)R_8$ ,  $-C(=O)NR_8R_9$ ,  $-$   
 $C(=O)NR_8OR_9$ ,  $-SO_cR_8$ ,  $-SO_cNR_8R_9$ ,  $-NR_8SO_cR_9$ ,  $-NR_8R_9$ ,  
 $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  
 15  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are the same or different and at each occurrence  
 independently hydrogen, alkyl, substituted alkyl, aryl, substituted  
 aryl, aralkyl, substituted arylalkyl, heterocycle, substituted  
 heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are  
 attached to form a heterocycle or substituted heterocycle;

$a$  and  $b$  are the same or different and at each occurrence independently  
 selected from 0, 1, 2, 3 or 4; and

$c$  is at each occurrence 0, 1 or 2.

25 In another embodiment, the present invention provides a method for treating  
 or preventing an inflammatory or autoimmune condition comprising administering to a  
 patient in need thereof an effective amount of an anilinopyrimidine derivative.

In another embodiment, the present invention provides a method for treating  
 or preventing a cardiovascular, metabolic or ischemic condition comprising administering to  
 30 a patient in need thereof an effective amount of an anilinopyrimidine derivative.

In another embodiment, the present invention provides a method for treating  
 or preventing an infectious disease comprising administering to a patient in need thereof an  
 effective amount of an anilinopyrimidine derivative.

In another embodiment, the present invention provides a method for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

5 In another embodiment, the present invention provides a method for treating or preventing stroke, epilepsy, Alzheimer's disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

10 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is a substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not pyridyl. When  $R_1$  is substituted, it is substituted with one or more substituents defined above. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.

15 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.

20 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl. When  $R_1$  is substituted, it is substituted with one or more substituents defined above. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.

25 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I),  $R_1$  is substituted or unsubstituted aryl, preferably phenyl or naphthyl. When  $R_1$  is a substituted aryl, it is substituted with one or more substituents defined above. Preferably, when substituted,  $R_1$  is substituted with a halogen, sulfone or sulfonamide.

30 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I),  $R_5$  and  $R_6$  taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle.

35 In another embodiment of the present methods, the nitrogen-containing non-aromatic heterocycle is piperazinyl, piperadinyl or morpholinyl. When the nitrogen-containing non-aromatic heterocycle is a substituted piperazinyl, piperadinyl or morpholinyl ring, the substituent is defined above. Preferably, when substituted, the substituent is alkyl, amino, alkylamino, alkylether, acyl, pyrrolidinyl or piperidinyl.

When used in the present methods, the anilinopyrimidine derivatives can be administered as a component of a composition that optionally comprises a pharmaceutically acceptable carrier or vehicle.

5 Conditions that may be treated using an anilinopyrimidine derivative, or using a pharmaceutical composition containing the same, include any condition that is responsive to IKK inhibition, particularly IKK-2 inhibition, and thereby benefit from administration of such an inhibitor. In general, the anilinopyrimidine derivatives of this invention may be used for the prevention and/or treatment of an inflammatory or autoimmune condition, a cardiovascular, metabolic or ischemic condition, an infectious  
10 disease or cancer. Representative conditions in this regard include (but not limited to) rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, Huntington's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, multiple sclerosis, lupus  
15 erythematosus, Type II diabetes, osteoporosis, erectile dysfunction, atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, myocardial infarction, stroke, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, multiple organ failure, psoriasis, eczema, dermatitis, epilepsy, Alzheimer's disease, Parkinson's disease, Lou Gerhig's disease, sepsis,  
20 conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip, viral infections (e.g., those caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, human T-cell leukemia virus or Epstein-Bar virus), cachexia, and cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth,  
25 pharynx, urinary bladder, ovary, bone marrow, thymus, breast, bone and uterine.

The anilinopyrimidine derivatives can also be used in cancer adjuvant therapy in combination with a cytotoxic agent or with radiation therapy.

The anilinopyrimidine derivatives are particularly useful in the treatment and/or prevention of bronchitis, multiple sclerosis, nasal polip and viral infections such as  
30 that caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, human T-cell leukemia virus or Epstein-Barr virus.

The anilinopyrimidine derivatives can be administered to a patient orally or parenterally in conventional and well known preparations, such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, injections, suspensions and syrups.  
35 Prior to administration, the anilinopyrimidine derivatives are typically formulated as a



pharmaceutical composition that contains an effective dosage amount of one or more of such compounds in combination with one (or more) pharmaceutically acceptable carrier(s). Suitable formulations in this regard may be prepared by methods commonly employed using conventional, organic or inorganic additives, such as an excipient (*e.g.*, sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), a binder (*e.g.*, cellulose, methylcellulose, hydroxymethyl cellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose or starch), a disintegrator (*e.g.*, starch, carboxymethylcellulose, hydroxypropylstarch, low substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (*e.g.*, magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), a flavoring agent (*e.g.*, citric acid, menthol, glycine or orange powder) a preservative (*e.g.*, sodium benzoate, sodium bisulfite, methylparaben or propylparaben), a stabilizer (*e.g.*, citric acid, sodium citrate or acetic acid), a suspending agent (*e.g.*, methylcellulose, polyvinyl pyrrolidone or aluminum stearate), a dispersing agent (*e.g.*, hydroxypropylmethylcellulose), a diluent (*e.g.*, water), and/or a base wax (*e.g.*, cocoa butter, white petrolatum or polyethylene glycol).

The dose of an anilinopyrimidine derivative to be administered to a patient, such as a human, is rather widely variable and subject to the judgment of the attending physician. The general range of effective administration rates of the anilinopyrimidine derivatives are from about 0.05 mg/day to about 250 mg/day, and typically from about 0.25 mg/day to 60 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation use, subject condition (such as weight), and/or the route of administration.

Further, the effect of the anilinopyrimidine derivatives can be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the anilinopyrimidine derivative may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

In certain embodiments, the anilinopyrimidine derivatives can be used in combination, *e.g.*, as an adjunct therapy, with at least one other therapeutic agent. An

anilinopyrimidine derivative and the other therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, an anilinopyrimidine derivative is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as or in a different composition from that comprising the anilinopyrimidine derivative. In another embodiment, an anilinopyrimidine derivative is administered prior or subsequent to administration of another therapeutic agent. As many of the disorders for which the anilinopyrimidine derivatives are useful in treating are chronic, in one embodiment combination therapy involves alternating between administering an anilinopyrimidine derivative and another therapeutic agent. The duration of administration of the anilinopyrimidine derivative or the other therapeutic agent can be, *e.g.*, one month, three months, six months, a year, or for more extended periods, such as the patient's lifetime. In certain embodiments, when a composition of the invention is administered concurrently with another therapeutic agent that potentially produces adverse side effects including, but not limited to, toxicity, the other therapeutic agent can advantageously be administered at a dose that falls below the threshold at which the adverse side effect is elicited.

The other therapeutic agent can be an anti-inflammatory agent. Useful anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetone, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide; leukotriene antagonists including, but not limited to, zileuton, aurothioglucose, gold sodium thiomalate and auranofin; and other anti-inflammatory agents including, but not limited to, colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone. Anti-inflammatory agents particularly useful for treating arthritis, including rheumatoid arthritis, include enbrel, infliximab, anakinra, celecoxib and rofecoxib.

The other therapeutic agent can be an anti-cancer agent. Useful anti-cancer agents include, but are not limited to, nitrogen mustards, such as cyclophosphamide, Ifosfamide, trofosfamide and Chlorambucil; nitrosoureas, such as carmustine (BCNU) and Lomustine (CCNU); alkylsulphonates, such as busulfan and Treosulfan; triazenes, such as Dacarbazine; platinum-containing compounds, such as Cisplatin and carboplatin; vinca alkaloids, such as vincristine, Vinblastine, Vindesine and Vinorelbine; taxoids, such as

paclitaxel and Docetaxol; epipodophyllins, such as etoposide, Teniposide, Topotecan, 9-aminocamptothecin, camptothecin and crisnatol; mytomycins, such as mytomycin C; DHFR inhibitors, such as methotrexate and Trimetrexate; IMP-dehydrogenase inhibitors, such as mycophenolic acid, Tiazofurin, Ribavirin and EICAR; ribonucleotide-reductase inhibitors, such as hydroxyurea and deferoxamine; uracil analogs, such as 5-fluorouracil, Floxuridine, Doxifluridine and Ratitrexed; cytosine analogs, such as cytarabine (ara C), cytosine arabinoside and fludarabine; purine analogs, such as mercaptopurine and thioguanine; anti-estrogens, such as Tamoxifen, Raloxifene and megestrol; LHRH agonists, such as goserelin and Leuprolide acetate; anti-androgens, such as flutamide and bicalutamide; vitamin D3 analogs, such as B 1089, CB 1093 and KH 1060; photodynamic therapeutic agents, such as vertoporphin (BPD-MA), Phthalocyanine, photosensitizer Pc4 and demethoxyhypocrellin A (2BA-2-DMHA); cytokines, such as interferon- $\alpha$ , interferon- $\gamma$  and tumor-necrosis factor; isoprenylation inhibitors, such as Lovastatin; dopaminergic neurotoxins, such as 1-methyl-4-phenylpyridinium ion; cell-cycle inhibitors, such as staurosporine; actinomycins, such as Actinomycin D and Dactinomycin; bleomycins, such as bleomycin A2, Bleomycin B2 and Peplomycin; anthracyclines, such as daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin and Mitoxantrone; MDR inhibitors, such as verapamil; and  $\text{Ca}^{2+}$  ATPase inhibitors, such as thapsigargin.

The following examples are offered by way of illustration, not limitation. To this end, it should be noted that one or more hydrogen atoms may be omitted from the drawn structure consistent with accepted shorthand notation of such organic compounds, and that one skilled in the art would readily appreciate their presence.

Retention time data for the following examples was obtained by one of two methods detailed as follows:

#### Method A

Column: YMC Pro C-18, 3.0  $\mu$  spherical silica gel, 4.0 x 50 mm, pore size 120Å.

Gradient: 0-10 min, 20%A - 90%A linear binary gradient.

Flow rate: 2.0 mL/min.

Mobile Phase: A, 0.1% formic acid in acetonitrile; B, 0.1% trifluoroacetic acid in water.

#### Method B

Column: YMC ODS-A, 5.0  $\mu$  spherical silica gel, 4.6 x 250 mm, pore size 120Å.

Gradient: 0-10 min, 20%A - 90%A linear binary gradient followed by 10-25 min, 100%A.

Flow rate: 1.0 mL/min.


Mobile Phase: A, 0.1% trifluoroacetic acid in acetonitrile; B, 0.1% trifluoroacetic acid in water.

## EXAMPLES

### EXAMPLE 1

#### SYNTHESIS OF

#### 4-{{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO} BENZAMIDE



#### (2E)-3-(Dimethylamino)- 1 -(4-chlorophenyl)prop-2-en-1-one

A solution of 1-(4-chlorophenyl)ethan-1-one (3.0g, 19.3 mmol) and N,N-dimethylformamide diisopropylacetal (20ml) was heated at 150°C for 16 hours. The reaction mixture was cooled to 0°C and treated with hexanes (20ml). The resulting solid was collected via filtration and washed with hexanes to provide the title compound: EI-MS (m/z) 209 [M+1]<sup>+</sup>.

#### 4-(4-Chlorophenyl)pyrimidine-2-thiol

To a solution of (2E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one (1.5g, 7.2 mmol) in ethanol (25 ml) was added thiourea (0.60g, 7.9 mmol) and potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) (1.19g, 8.63 mmol). The resulting suspension was heated to 85°C for 12 hours then cooled to ambient temperature. The resulting solid was collected and thoroughly washed with water and hexanes to provide a beige solid: EI-MS (m/z) 222 [M+1]<sup>+</sup>.

#### 4-(4-Chlorophenyl)-2-methylthiopyrimidine

4-(4-Chlorophenyl)pyrimidine-2-thiol (1.2 g, 5.39 mmol) was taken in 10 ml of an aqueous potassium hydroxide (0.453g, 5.39 mmol) solution. Iodomethane (503 µl, 5.39 mmol) was added at ambient temperature and the reaction mixture was allowed to stir for 30 minutes. The resulting white solid was collected via filtration and washed with minimal water and hexanes to provide the title compound: EI-MS (m/z) 237 [M+1]<sup>+</sup>.

4-(4-chlorophenyl)-2-(methylsulfonyl)pyrimidine

To a solution of 4-(4-chlorophenyl)-2-methylthiopyrimidine (1.1 g, 4.65 mmol) in acetone (30 ml) and water (10 ml) was added oxone (7.14g, 11.62 mmol). The reaction mixture was stirred for 18 hours then diluted with water and extracted into dichloromethane. The extracts were dried over magnesium sulfate, filtered and concentrated to provide a white solid: EI-MS (m/z) 269 [M+1]<sup>+</sup>.


4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzamide

To a solution of 4-(4-chlorophenyl)-2-(methylsulfonyl)pyrimidine (0.10g, 0.37 mmol) and 4-aminobenzamide in 2-propanol (3 ml) was heated to 120°C in a sealed vessel for 14 hours. The crude material was concentrated and purified by preparative HPLC to provide the title compound as a beige solid: LC/MS Retention Time; 6.30 min (Method A), M+1; 325.

EXAMPLE 2

## ALTERNATIVE SYNTHESIS OF

## 4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZAMIDE

N-{(4-Aminocarbonyl)phenyl}guanidine nitrate

To a stirred suspension of 4-aminocarbonylaniline (20 g, 147 mmol) and cyanamide (14.2g, 338 mmol) in 70 mL of ethanol was added concentrated nitric acid (20 mL) dropwise. The reaction mixture was heated at reflux overnight, and cooled. Volatile matters were evaporated to give a thick oil. The residue was taken up in methylene chloride and methanol to afford yellow solid. This material was filtered, washed with ether and water and dried in vacuo at 50°C to afford the desired product (17.5 g, 66% yield): LC/MS Retention Time; 0.63 min (Method A), M+1; 179.




4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}benzamide



To a solution of (2E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one (0.10 g, 0.48 mmol), 4-(amidinoamino)benzamide nitrate (0.116 g, 0.48 mmol), and potassium carbonate (0.132g, 0.96 mmol) in ethanol (10 ml) with was heated to 120°C overnight in a sealed vessel. The reaction mixture was cooled to room temperature and the resulting solid was collected then washed with ethanol, water, and diethyl ether to provide the title compound as a beige solid, identical in all respects with the compound prepared in Example 1.





### EXAMPLE 3

#### SYNTHESIS OF REPRESENTATIVE COMPOUNDS

The compounds listed below were prepared according to the procedure of Example 2 using the appropriate methylketone as the starting material.

Compound Number	Structure	MOL. WEIGHT	RT, min	M+1
3-1		315.335	5.67	316
3-2		296.353	5.53	296
3-3		324.314	5.93	325




3-4		290.325	5.77	291
3-5		320.35	6.07	321

5	3-6		279.302	4.8	280
10	3-7		464.931	6.47	4.65
15	3-8		431.474	5.53	432
20	3-9		431.474	5.58	432

30

35












5	3-10		449.576	4.62	450
10	3-11		407.539	4.62	408
15	3-12		462.619	4.47	463




25

30

35




5	3-13		431.474	5.53	432
10	3-14		380.47	5.55	381
15	3-15		412.468	5.04	413
20	3-16		565.57	1.97	452
25	3-17		452.537	5.48	453
30					
35					

5	3-18		390.388	7.18	391
10	3-19		346.432	7.43	347
20	3-20		398.488	7.4	399
30	3-21		430.486	6.64	431
35					

5	3-22	 <chem>Nc1ccc(Nc2ncnc(c2)c3ccc(Br)cc3)cc1</chem>	369.221	6.88	369
10	3-23	 <chem>CCOC1=CC=C(N2C(=NC(=C2)Nc3ccc(N)cc3)N=C1)C=C</chem>	335.365	5.8	336
15					
20	3-24	 <chem>COC1=CC=C(N2C(=NC(=C2)Nc3ccc(N)cc3)N=C1)C=C</chem>	321.339	5.5	322
25					




30

35

5	3-25		334.381	4.04	335
10	3-26		373.458	5.57	374
20	3-27		335.322	5.87	336




30

35

5	3-28		362.431	6.77	363
10	3-29		333.393	5.07	334
15					
20	3-30		375.43	5.47	376
25					




30

35

5	3-31		359.215	6.57	359
10	3-32		359.215	6.47	359
15					
20	3-33		374.321	6.43	375
25					

30




35

5	3-34		340.384	6.33	341
10	3-35		411.487	6.73	412
15					
20	3-36		356.387	4.27	357
25					

30




35



5	3-37	 <chem>Cc1nc(Nc2ccc(NC(=O)O)cc2)n(Cc3ccc(Cl)cc3)c1</chem>	338.797	6.37	339
10	3-38	 <chem>Fc1cc(Cl)c(Cl)cc1C2=CN=C(Nc3ccc(NC(=O)O)cc3)N2</chem>	377.205	6.50	377
15					
20	3-39	 <chem>Clc1cc(Cl)c(Cl)cc1C2=CN=C(Nc3ccc(NC(=O)O)cc3)N2</chem>	393.66	6.67	393
25					

30

35

5	3-40		334.334	4.7	335
10	3-41		330.346	11.176	331
15					
20	3-42		346.413	10.288	347
25					

30

35

5

10




15





20





25





30

35





3-43		500.577	10.48	501.3
3-44		467.53	9.956	468.3
3-45		468.515	11.268	469.3



5	3-46		477.5372	12.74	478.3
10	3-47		443.5481	11.292	444.6
15	3-48		485.4638	11.396	486.3
20	3-49		486.573	8.548	487.3

5	3-50		401.4677	9.664	402
10	3-51		450.3428	8.684	378.4
15	3-52		469.4648	11.36	470.3
20	3-53		521.4968	12.204	522.3

5	3-54		501.5308	12.072	502.3
10	3-55		444.5362	8.696	445.4
15	3-56		500.3498	9.74	428.4
20	3-57		480.3638	11.084	482.2
25					
30					

35


5	3-58		457.5749	12.344	458.3
10	3-59		500.5998	9.924	501.5
15	3-60		368.8223	10.624	369.2
20	3-61		564.6428	6.49	565.4
25					
30					

5	3-62		415.4945	10.268	416.3
10	3-63		470.3579	12.05	470.3
15					

EXAMPLE 4

20 SYNTHESIS OF 4-[(4-{4-[(4-CHLOROPHENYL)SULFONYL]PHENYL}PYRIMIDIN-2-  
YL)AMINO]BENZAMIDE


25



30

35






To a stirred solution of *p*-chlorobenzenethiol (1) (3.2g, 0.022 mol) in DMF (40 mL) was added NaH (60% dispersion in mineral oil, 0.8g). After the effervescence had ceased, *p*-chlorobenzenethiol (0.011 mol, 0.55 equiv) was added. The solution was then stirred at 110°C for 3 h. The mixture was cooled to room temperature and then diluted with ether (150 mL). The ethereal suspension was washed with 5% NaOH (aq, 50 mL), 3% HCl (aq, 2 x 50 mL), filtered, and concentrated to afford 2.88 g of *p*-chlorophenylthioacetophenone (2) (100%). Biarylsulfide (2) was then dissolved in acetone/water (4:1, v/v, 100 mL). OXONE (13.5 g, 2.2 equiv) was added to the solution. The reaction was stirred 4 h at room temperature. After this time, the acetone was removed *in vacuo*. The mixture was diluted in ether (100 mL) and water (100mL). The mixture was shaken and the layers separated. The ether layer was dried (MgSO<sub>4</sub>), filtered, and concentrated to afford 2.02 g (62%) of sulfone 3. Sulfone (3) was then dissolved in dimethylformamide dimethyl acetal (15 mL) and heated to 110°C for 12 h. The reaction mixture was then concentrated to remove excess in dimethylformamide dimethyl acetal. A

portion of the intermediate ene-amino ketone (0.38 g, 1.09 mmol) was taken up in ethanol (20 mL). To this solution was added  $K_2CO_3$  (0.45 g, 3 equiv) and 4-guanadinobenzamide (4) (0.26 g, 1 equiv). The reaction mixture was heated in a sealed tube at 100°C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then  
5 filtered. The solid was washed with water and ethanol. A portion of the material was purified by preparatory HPLC to afford 15 mg of the desired compound, which was found to be 100% pure by analytical HPLC. LCMS ( $M+H=465.0$  @ 6.47 min.(Method A)).

#### EXAMPLE 5

10 SYNTHESIS OF 4-({4-[4-(4-PYRIDYLSULFONYL)PHENYL]PYRIMIDIN-2-YL}AMINO)BENZAMIDE




The above compound was made according to the procedure of Example 4  
25 from 2-mercaptopyridine and the appropriate thiol as the starting materials. LCMS:  
( $M+H=432.1$ , @ 5.50 min.(Method B)).

30

35

EXAMPLE 6


## SYNTHESIS OF 4-({4-[4-(2-PYRIDYLSULFONYL)PHENYL]}PYRIMIDIN-2-YL}AMINO)BENZAMIDE



The above compound was made according to the procedure of Example 4 from 2-mercaptopyridine and the appropriate thiol as the starting materials. LCMS (M+H=432.0 @ 5.58 min.(Method B)).

EXAMPLE 7


## SYNTHESIS OF 4-({4-[4-(3-PYRIDYLSULFONYL)PHENYL]}PYRIMIDIN-2-YL}AMINO)BENZAMIDE



The above compound was made according to the procedure of Example 4 from 3-mercaptopyridine and the appropriate thiol as the starting materials. LCMS (M+H=432.1 @ 5.55 min.(Method B)).

EXAMPLE 8


## SYNTHESIS OF 4-({4-[4-(3-HYDROXYPROPYLTHIO)PHENYL]PYRIMIDIN-2-YL} AMINO)BENZAMIDE




The above compound was made according to the procedure of Example 4 from 3-mercaptopropanol and the appropriate thiol as the starting materials. LCMS (M+H=381.0 @ 5.55 min.(Method B)).

EXAMPLE 9

## SYNTHESIS OF 4-[(4-{4-[(3-HYDROXYPROPYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE





To a solution of 3-mercapto-1-propanol (5 g, 0.054 mol) in DMF (40 mL) was added NaH (2.2 g, 60% dispersion in mineral oil). After the bubbling had ceased, *p*-chloroacetophenone (5.25 mL, 0.041 mol, 0.75 equiv) was added and the mixture was stirred at 100°C for 3 h. The reaction was cooled, diluted with ether (200 mL), and washed with 5% HCl (aq) (2 x 30 mL), water (2 x 50 mL), and then brine (40 mL). The ether layer was dried (MgSO<sub>4</sub>), filtered, and concentrated to afford thioaryl ketone (5) (6.1 g, 0.29 mol, 72%). Ketone (5) (0.72 g, 3.4 mmol) was dissolved in acetone/water (4:1 v/v, 20 mL). OXONE® (4.2 g) was added and the mixture was stirred for 2 h. The mixture was then concentrated, diluted with ether (75 mL), washed with water (3 x 50 mL), and then brine (50 mL). The ether layer was then dried (MgSO<sub>4</sub>), filtered, and concentrated to afford to aryl sulfone (6). The title compound was prepared as previously described in Example 4 from ketone (6) to afford 39 mg (3%) of analytically pure material. LCMS: (M+H=413.0 @ 5.04 min. (Method A)).

EXAMPLE 10

## SYNTHESIS OF 4-({4-[4-(3-MORPHOLIN-4-YLPROPYLTHIO)PHENYL]PYRIMIDIN-2-YL}AMINO)BENZAMIDE

5

10






15


20

25

30

35





20 Acetophenone (5) was then taken up on toluene (50 mL). To this solution was added ethylene glycol (2.6 mL, 2 equiv) and *p*-toluenesulfonic acid (0.7g). The reaction was refluxed with a Dean Stark trap for 2 - 3 h. After azeotropic removal of water, the reaction was cooled and then washed with 10%  $\text{NaHCO}_3$  (aq, 50 mL), water (50 mL), and brine (50 mL). The organic extract was dried ( $\text{MgSO}_4$ ), filtered, and concentrated. The crude acetal was then taken up in  $\text{CH}_2\text{Cl}_2$  (20 mL). In a separate flask,  $(\text{COCl})_2$  (2.26 mL, 26.0 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (20 mL) and cooled to  $-78^\circ\text{C}$ . DMSO (3.7 mL, 52.0 mmol) in  $\text{CH}_2\text{Cl}_2$  (5 mL) was then added to the cold solution dropwise. This mixture was stirred for 2 min, after which the crude acetal was added in  $\text{CH}_2\text{Cl}_2$  (20 mL). After stirring 15 min,  $\text{Et}_3\text{N}$  (16.5 mL, 5 equiv) was added slowly. The resulting mixture was stirred 5 min, and then let warm to room temperature over 1 h. The mixture was then poured into a separatory funnel and washed with 5%  $\text{NaHCO}_3$  (100 mL). The organic layer was then washed with brine (50 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated to afford crude aldehyde (7). Aldehyde (7) (0.5 g) was then taken up in MeOH/AcOH (10 mL). To this solution was added morpholine (0.21 mL). The mixture was stirred 10 min, after which time  $\text{NaBH}_3\text{CN}$  (0.19 g) was added. After 30 min, the reaction mixture was concentrated, basified with 3 M NaOH, and extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 15 mL). The organic extracts

25


30

35

were concentrated and then taken up in acetone/water (9:1 v/v, 20 mL). *P*-TsOH (0.1 g) was then added to the solution and the mixture was stirred 12 h. After this time, the mixture was concentrated, basified with 1 M NaOH, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 15 mL). The organic extracts were then dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford crude aryl ketone (8), which was taken up in dimethylformamide dimethyl acetal (15 mL) and heated to 100°C for 12 h. The mixture was then concentrated down and taken up in EtOH (15 mL). To this solution was added K<sub>2</sub>CO<sub>3</sub> (0.31 g) and 4-guanadinobenzamide (4) (0.14). The reaction mixture was heated in a sealed tube at 100°C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then filtered. The solid was washed with water and ethanol. The material was purified by preparatory HPLC to afford the titled compound (33 mg, 4%): LCMS 4.62 min. (Method A), M+H = 450.


#### EXAMPLE 11

#### SYNTHESIS OF 4-[(4-{4-[3-(DIMETHYLAMINO)PROPYLTHIO]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE



The titled compound was prepared by the procedure of Example 10, except dimethylamine was used in place of morpholine during the reductive amination of aldehyde (7). LCMS (M+H=408.0 @ 4.62 min.(Method B)).



EXAMPLE 12SYNTHESIS OF 4-[(4-{4-[3-(4-METHYLPYPERAZINYL)PROPYLTHIO]  
PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE

The titled compound was prepared by the procedure of Example 10, except N-methylpiperazine was used in place of morpholine in the reductive amination of aldehyde (7). LCMS (M+H=463.0 @ 4.47 min.(Method B)).

**EXAMPLE 13****SYNTHESIS OF 4-[4-{4-[(1-METHYL-4-PIPERIDYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE**

5


10

15

20


25

30



4-mercaptopyridine (2.8 g, 25.0 mmol) was dissolved in DMF (25 mL).  
 NaH (lg, 60% dispersion in mineral oil) was then added to the solution. After the  
 effervescence had ceased, *p*-chloroacetophenone (1.4 mL, 11 mmol) was added and the

mixture was heated to 110°C for 14 h. After this time, the mixture was cooled, diluted with ether (100 mL). The mixture was washed with 5% NaOH (2 x 50 mL), water (2 x 50 mL), and brine (50 mL). The ethereal extract was dried (MgSO<sub>4</sub>), filtered, and concentrated. The resulting oil was purified by flash chromatography (9:1 to 7:3 hexanes/ethyl acetate gradient). Concentration of the desired fractions afforded 1.37g (54%) of thioacetophenone (9). Sulfide (9) (1.37 g) was then dissolved in acetone/water (9:1 v/v, 35 mL). To this solution was added OXONE® (7.4 g, 2 equiv). The mixture was stirred for 2 h. The mixture was then concentrated, neutralized with 10% NaHCO<sub>3</sub>, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 50 mL). The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford diarylsulfone (10) (1.25 g, 80%). Sulfone (10) (0.53 g, 2.0 mmol) was dissolved in THF (7 mL). To this solution was added Super Hydride® (6.3 mL, 1 M in THF) at room temperature. The solution was stirred at room temperature for 1 h, followed by quenching with MeOH (0.6 mL). The mixture was then concentrated. The residue was taken up in 1 N HCl (50 mL). The aqueous mixture was extracted with ether (3 x 50 mL). The organic layers were discarded. The aqueous layer was basified and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 15 mL). The organic layers were concentrated. The residue was taken up in AcOH/MeOH (1:1 v/v, 10 mL). CH<sub>2</sub>O (37% aq, 1 mL) and NaBH<sub>3</sub>CN (0.1 g) were added. The mixture was stirred 30 min. The mixture was then concentrated, basified with 10% NaOH (aq) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 15 mL). The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford crude ketone (11). Aryl ketone (10) was refluxed in dimethylformamide dimethyl acetal (15 mL) and heated to 100°C for 12 h. The mixture was then concentrated down and taken up in EtOH (15 mL). To this solution was added K<sub>2</sub>CO<sub>3</sub> (0.31 g) and 4-guanadinobenzamide (4) (0.14 g). The reaction mixture was heated in a sealed tube at 100°C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then filtered. The solid was washed with water and ethanol. The material was purified by preparatory HPLC to afford 6.0 mg (0.5% from sulfone (10)) of the title compound. LCMS (M + H = 452 @ 6.13 min.(Method A)).

**EXAMPLE 14****SYNTHESIS OF 4-[(4-{4-[(4-METHYLPYPERAZINYL)SULFONYL]PHENYL}  
PYRIMIDIN-2-YL)AMINO]BENZAMIDE**

*N*-Methylpiperazine (1.16 mL, 0.01 mol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (30 mL) and  $\text{Et}_3\text{N}$  (4.4 mL, 0.033 mol). The solution was cooled to  $0^\circ\text{C}$  and 4-acetylbenzenesulfonyl chloride (2.29 g, 0.01 mol) was added at once. The reaction was stirred for 15 min., poured into a separatory funnel, and extracted with water (3 x 20 mL) and then brine (10 mL). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated to afford aryl ketone (12). Ketone (12) was carried on without purification to make the title compound as described in Example 13. An analytical sample was purified by preparatory HPLC (0.028 mg, 0.6 %): LCMS ( $\text{M}+\text{H}=453.2$  @ 5.48 min.(Method A)).

EXAMPLE 15

## SYNTHESIS OF

4-{2-[(4-CARBAMOYLPHENYL)AMINO]PYRIMIDIN-4-YL}  
BENZOIC ACID


5

10

15

20

25



30

A mixture of ethyl 4-acetylbenzoate (3.00 g, 15.62 mmol) and N,N-dimethylformamide dimethyl acetal (6.2 g, 52.10 mmol) was refluxed for 18 hours, cooled and concentrated to give ethyl 4-[(2E)-3-(dimethylamino)prop-2-enoyl]benzoate quantitatively. A solution of ethyl 4-[(2E)-3-(dimethylamino)prop-2-enoyl]benzoate, potassium carbonate (3.55 g, 25.74 mmol), and 4-(amidinoamino)benzamide (3.10 g, 12.87 mmol) in ETOH (120 mL) was refluxed for 18 hours. The mixture was cooled, filtered, and

35

washed with ETOH, water, then ether respectively to give ethyl 4-{2-[(4-carbamoylphenyl)amino]pyrimidin-4-yl}benzoate (2.60 g, 46 % yield). This compound was refluxed for 2 hours in ETOH (30 mL), water (20 mL), and NaOH (0.640 g, 16 mmol). The reaction mixture was cooled, acidified to pH 3, and filtered to give 1.00 gram (42 % yield)  
5 of the titled compound. HPLC/ES-MS (20-100% acetonitrile): R.T. 4.7 min.(Method A) ;  
(m/z) 335 [M+ 1]<sup>+</sup>.

10

15

20

25

30


35

EXAMPLE 16


## SYNTHESIS OF

(4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}  
PHENYL)-N,N-DIMETHYL CARBOXAMIDE


5



10




15



20

25

30



35

4-Guanidino-benzoic Acid Methyl Ester

To a stirred suspension of 4-guanidino benzoic acid (20.0g, 93mmol) in methanol (600mL) was added thionyl chloride (12mL) drop wise. The reaction mixture was stirred at room temperature overnight. The reaction was concentrated *in vacuo* to give a white powder. The crude material was dissolved in dichloromethane and evaporated to provide the title compound as a white powder (17.95g, 100% yield): HPLC Retention Time; 1.27 min (Method A). M+1; 193.

(2E)-3-Dimethylamino-1-(4-chlorophenyl)prop-2-en-1-one

A solution of 1-(4-chlorophenyl)ethane-1-one (35.0g, 226 mmol) and N, N Dimethylformamide diisopropylacetal (35mL) was heated to reflux for 16 hours. The reaction mixture was cooled to room temperature and treated with hexanes (50mL). The resulting solid was collected via filtration and washed with hexanes to provide the title compound as a yellow solid (47.12g, 99% yield): HPLC Retention Time; 6.45 min (Method B). M+1; 209.

4-[4-(4-Chlorophenyl)-pyrimidin-2-ylamino]benzoic Acid

A Solution of 4-guanidino-benzoic acid methyl ester (17.95g, 93mmol), (2E) 3-dimethylamino-1-(4-chlorophenyl)prop-2-en-1-one (19.44g, 93mmol, and potassium carbonate (38.50g, 279mmol) in 1-propanol was heated to reflux for 24 hours. The reaction mixture was cooled to room temperature. The resulting solid was collected via filtration and washed with ethanol to provide the title compound which was used without further purification. EI MS(m/z) 339 [M+1]<sup>+</sup>. To a suspension of 4-[4-(4-chlorophenyl)-pyrimidin-2-ylamino]benzoic acid methyl ester in methanol (100mL) was added 5N NaOH (100mL). The reaction mixture was heated to reflux for 4 hours and then cooled to room temperature. The resulting solid was collected via filtration, washed with hexanes, and dried *in vacuo* to provide the title compound as a yellow solid (27.36g, 100% yield): HPLC Retention Time; 7.29 min (Method A). M+1; 325.

(4-{[4-(4-Chlorophenyl)-pyrimidin-2-yl]amino}phenyl)-N,N-dimethyl carboxamide

To 4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino} benzoic acid (200 mg, 0.615 mmol) is added thionyl chloride (4 mL) along with a catalytic amount of DMF at room temperature. The resulting suspension is then refluxed for a period of 1 hour resulting in a clear pale yellow solution which was concentrated *in vacuo*. To the flask was then added a solution of dimethylamine (615 µL of a 2.0 M solution in THF, 1.23 mmol) and



triethylamine (124 mg, 1.23 mmol) in tetrahydrofuran (4.5 mL). The solution was then stirred for 18 hours at room temperature, diluted with water (5 mL) and filtered.

Purification of the remaining solid by preparative HPLC yielded the title compound.


HPLC/ES-MS: RT 6.74 min.(Method A); (m/z) 353 [M+1]<sup>+</sup>.

5

### EXAMPLE 17

#### SYNTHESIS OF FURTHER REPRESENTATIVE COMPOUNDS

10



15

20





Compounds listed below were prepared according to the above procedure:

25

Compound Number	Structure	MOL. WEIGHT	RT, min	M+1
17-1		366.85	7.02	367

30





35

5	17-2		352.823	6.74	353
10	17-3		338.797	6.43	339
15	17-4		442.948	7.97	443
20	17-5		428.921	7.83	429

25

30





35





5	17-6		418.857	7.53	419
10	17-7		435.312	7.80	436
15	17-8		435.312	7.80	436
20	17-9		401.855	6.82	402





25





30

35

5	17-10		401.855	6.82	402
10	17-11		414.894	7.67	415
15	17-12		416.866	6.87	417
20	17-13		400.867	7.53	401

17-14		444.92	7.40	445
17-15		430.893	7.50	431
17-16		460.919	7.60	461
17-17		443.936	5.97	444





17-18		397.274	6.77	397
17-19		429.909	5.07	430
17-20		408.887	6.1	409
17-21		432.913	4.53	433

5	17-22		409.875	5.57	410
10	17-23		449.983	4.73	450
15	17-24		382.849	6.17	383
20	17-25		382.849	6.1	383




25





30

35

17-26		382.849	6.17	383
17-27		408.887	6.28	409
17-28		394.86	5.87	395
17-29		542.617	5.9	543











17-30		594.649	5.86	595
17-31		408.524	5.58	409
17-32		548.708	5.89	549

5	17-33		491.613	5.32	492
10	17-34		543.645	6.73	544
15	17-35		421.922	5.92	422
20	17-36		493.992	8.04	494





30

35





5	17-37		449.933	11.2	450
10	17-38		420.922	7.7	421
15	17-39		414.894	7.8	415
20	17-40		482.891	8.1	483





17-41		442.948	8.07	443
17-42		493.79	8	495
17-43		422.957	8.4	423
17-44		406.915	7.9	407

5

17-45		428.921	7.8	429
17-46		458.903	7.7	459
17-47		508	6.2	508
17-48		456.974	7.5	457





35

17-49		474.946	6.7	475
17-50		467.954	6.7	468
17-51		488.973	7.6	489
17-52		550.888	8.5	551

5	17-53		505.018	7.8	505
10	17-54		449.94	5.9	450
15	17-55		420.941	8.2	421
20	17-56		442.948	8	443

30

35

5	17-57		432.953	8.2	433
10	17-58		404.855	7.5	405
15	17-59		482.891	8.1	483
20	17-60		504.971	7.6	505

30

35



5

10





15





20

25

30

35

17-61		432.884	7.8	433
17-62		463.366	8.1	463
17-63		428.921	7.9	429
17-64		458.903	7.8	460

5	17-65		472.93	7.8	473
10	17-66		420.941	8.1	421
15	17-67		474.946	7.8	475
20	17-68		483.784	8.2	483
25					
30					

5

10





15





20

25

30

35

17-69		438.913	7.8	439
17-70		432.884	7.1	433
17-71		392.888	7.8	393
17-72		396.876	7.2	397

5	17-73		474.946	7.8	475
10	17-74		463.366	8.2	463
15	17-75		442.948	8.1	443
20	17-76		444.92	7.8	445
25					
30					

5

10





15





20

25

30

35

17-77		428.921	7.9	429
17-78		444.92	5.7	445
17-79		493.79	8	495
17-80		446.911	7.9	447

5	17-81		456.974	8.2	457
10	17-82		460.919	7.3	461
15	17-83		471.001	8.5	471
20	17-84		511.78	8.2	513
25					
30					

5

10





15





20

25




30




35

17-85		463.366	8	463
17-86		451.955	5.9	452
17-87		420.941	8.1	421
17-88		449.339	7.9	449

5	17-89		472.93	7.8	473
10	17-90		521.145	9.8	521
15	17-91		396.832	6.3	397
20	17-92		481.981	7.6	482
25					
30					









17-93		471.989	7.7	472
17-94		366.85	6.6	367
17-95		500.881	7.5	501

5	17-96		432.884	7.1	433
10	17-97		438.913	7.5	439
15	17-98		444.92	7.7	445
20					
25					

30

35




17-99		537.843	7.4	539
17-100		428.921	7.3	429
17-101		442.948	7.4	443





5	17-102		420.941	7.5	421
10	17-103		440.932	7.3	441
15	17-104		451.915	6.2	453

25

30




35





5	17-105		431.881	4.9	432
10	17-106		396.876	5.71	397
15	17-107		422.957	7.7	423
20					
25					
30					
35					

5	17-108		465.038	8.6	465
10	17-109		483.784	7.8	483
15	17-110		456.974	7.7	457
20	17-111		456.974	7.6	457





30

35





17-112		511.78	7.4	513
17-113		449.339	7.4	449
17-114		483.784	7.8	485





17-115		392.888	7.1	393
17-116		446.911	7.2	447
17-117		378.861	6.8	379
17-118		429.909	4.9	430











5	17-119		440.892	6.5	441
10	17-120		408.872	6.5	409
15	17-121		440.892	6.4	441
20	17-122		415.882	4.9	416
25					
30					





35

5	17-123		422.898	6.6	423
10	17-124		439.904	7.1	440
15	17-125		418.882	7.2	419
20	17-126		364.834	6.4	365
25					
30					

17-127		407.903	4.8	408
17-128		528.009	5.3	528
17-129		435.913	6.8	436
17-130		492.02	7.4	492

17-131		421.886	6.8	422
17-132		366.85	7.4	367
17-133		394.86	7.2	395
17-134		512.01	7.6	512

17-135		499.999	7.8	500
17-136		516.987	7.9	515
17-137		465.939	7.4	466
17-138		407.884	7.2	408

5	17-139		450.924	7.4	451
10	17-140		468.986	8.3	469
15	17-141		493.008	7.1	493
20	17-142		437.929	4.6	438
25					
30					

5





10

15





20

25

30

17-143		537.971	8.3	538
17-144		390.872	7.7	391
17-145		437.929	4.6	438
17-146		465.038	8.4	465

35

5	17-147		443.936	6.3	444
10	17-148		470.962	6.3	473
15	17-149		487.964	8	488
20	17-150		486.016	6.3	486



5

10





15





20




25





30

35

17-151		443.936	6.3	444
17-152		435.956	4.6	436
17-153		437.972	4.7	438
17-154		409.919	4.6	410

17-155	 <chem>COc1ccc(cc1)CCNC(=O)c2ccc(cc2)Nc3cc(Cl)ccn3</chem>	458.947	7.4	365
17-156	 <chem>C1CC1CNC(=O)c2ccc(cc2)Nc3cc(Cl)ccn3</chem>	364.834	7.2	365
17-157	 <chem>CC(=O)Nc1ccc(cc1)Nc2cc(Cl)ccn2</chem>	428.921	7.9	429
17-158	 <chem>c1ccc(cc1)N2CCN(CC2)C(=O)c3ccc(cc3)Nc4cc(Cl)ccn4</chem>	469.974	8	470

17-159		487.945	6.3	488
17-160		449.94	5.8	450
17-161		484.988	4.4	485

5	17-162		463.966	6	464
10	17-163		449.94	5.8	450
15	17-164		464.998	4.8	465
20	17-165		443.936	5.6	444
25					
30					

5

10





15





20

25

30

35





17-166		349.78	7.3	350
17-167		422.914	12.167	423.0
17-168		392.888	6.983	393.2
17-169		476.021	8.92	476.2





5	17-170		421.886	10.436	422.2
10	17-171		461.994	8.717	462.2
15	17-172		465.9822	8.45	466.9
20	17-173		407.903	9.38	408

25





30





35

17-174		449.983	10.27	450
17-175		421.93	9.37	422
17-176		407.903	9.37	408
17-177		407.903	9.42	408

17-178		436.901	9.09	437
17-179		490.629	8.02	491
17-180		489.597	8.17	490
17-181		491.613	8.42	492



5	17-182		407.859	10.23	408
10	17-183		407.903	9.42	408
15	17-184		449.94	11.07	450
20	17-185		405.887	9.3	406





5	17-186		435.956	9.86	436
10	17-187		476.021	10.66	477
15	17-188		421.9296	10.63	422
20	17-189		469.9736	10.57	470

20

25





30

35

5	17-190		421.9296		
10	17-191		491.0359	9.03	491.3
15	17-192		465.9822	9.88	466.3
20	17-193		461.9942	10.48	462.3

30

35

5	17-194		451.9554	9.7	452.3
10	17-195		451.9554	9.7	452.3
15	17-196		505.0627	505.4	11.976
20	17-197		476.021	4.82	476.3

30

35

5

10





15





20





25





30

35

17-198		481.981	4.35	482
17-199		465.982	4.66	466.3
17-200		433.941	4.59	434
17-201		477.993	4.63	478.3

5	17-202		479.025	0.79	479.3
10	17-203		491.036	3.53	491.3
15	17-204		478.981	7.19	479.4
20					
25	17-205		545.015	6.86	553.4
30					



5	17-206		556.067	7.23	556.4
10	17-207		508.019	7.9	508.4
15	17-208		574.381	5.89	465.4
20	17-209		630.444	3.56	631.3

5	17-210		614.445	5.64	505.4
10	17-211		406.871	5.86	436.4
15	17-212		477.9932	478.5	7.583
20	17-213		492.02	8.05	492.5

30

35




17-214		476.021	8.817	476.5
17-215		437.92		438

EXAMPLE 18SYNTHESIS OF 4-{{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZOIC  
ACID PIPERAZINE AMIDE HYDROCHLORIDE

5

10


15



Hydrogen chloride gas was bubbled slowly in a solution of tert-butyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzoic acid piperazine amide (3.0 g, 6.1 mmol) in acetic acid (61 mL) for 20 minutes. The solution was concentrated and dried on a vacuum pump to give 2.6 g (99%) of the title compound; ES-MS,  $m/z$  394 ( $M+1$ )<sup>+</sup> LC/MS Retention Time, 5.84 min.(Method A).

EXAMPLE 1925 SYNTHESIS OF 4-{{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZOIC  
ACID 4-ETHYL PIPERAZINE AMIDE

30



A solution of 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl piperazine ketone (0.5 g, 1.54 mmol), N-ethylpiperazine (0.18 g, 1.54 mmol), 1-(3-

dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (0.44 g, 2.31 mmol) and hydroxybenzotriazole (0.31 g, 2.31 mmol) in dimethylformamide (15 mL) was stirred for 18 h. Water (50 mL) was added and the solid was filtered. The solid was purified on preparatory HPLC (C-18 column, 30% acetonitrile to 100% acetonitrile in water-both containing 0.1% trifluoroacetic acid) to give the titled compound, 0.27 g (42%) yield; ES-MS, m/z 422 (M+1)<sup>+</sup> LC/MS Retention Time, 5.92 min.(Method A).


EXAMPLE 20  
SYNTHESIS OF 4-ACYLAMINOPIPERIDINES

10

15

20

25



4-Aminopiperidyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl} Ketone Hydrochloride

30

35

(tert-Butoxy)-N-{1-[[4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl]carbonyl}(4-piperidyl)]carboxamide (4.00g, 7.87 mmol) was stirred in 50 mL EtOH followed by addition of anhydrous HCl gas. The reaction was stirred for 30 min. then concentrated down to a residue. To this was added a small amount of EtOH followed by dilution with ether. A yellow solid formed which was filtered and dried to give 3.00 grams of 4-aminopiperidyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl} ketone


hydrochloride: HPLC Retention time; 5.89 min. (Method B) M+1; 408.4

N-{1-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]-4-piperidyl}acetamide

- 5                      Stirred 4-aminopiperidyl 4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl ketone hydrochloride (300 mg , 0.582 mmol) in 10 mL THF with triethylamine (0.293 mg , 2.91 mmol). Acetic anhydride (89 mg , 0.873 mmol) was added and the reaction was stirred for 40 minutes. The solution was concentrated down and purified by preparative HPLC to give N-{1-[(4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]-4-piperidyl}acetamide (0.120 g , 46 % yield): HPLC Retention time; 6.92 min. (Method B) M+1; 450.4
- 10

Compounds listed below were prepared according to the above procedure.

15





Compound Number	Structure	MW	RT, min	M+1
20-1		449.94	6.92	450.4



20

25

30

35

20-2		531.013	7.49	531.4
20-3		518.039	7.6	518.4
20-4		521.018	7.19	521.4
20-5		478.981	7.18	479.4

5	20-6		479.965	7.3	480.2
10	20-7		541.052	7.68	541.4

15


20

25

30

35

EXAMPLE 21

SYNTHESIS OF PIPERAZINEACETIC ACID AMIDES

30 Ethyl 2-{4-[(4-{[4(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl) carbonyl] piperazinyl}acetate

4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzoic acid (5g, 15.3 mmol) was dissolved in dimethylformamide. The HOBT(2.82 g, 18.4 mmol) and EDCI(3.53 g, 18.4 mmol) were then added. The reaction stirred for 15 minutes then ethyl-2-piperazinylacetate (2.14 mL, 18.4 mmol) was added. The reaction was stirred overnight at room temperature. Water (150 mL) was added. The solid was collected by filtration, and

35

purified by silica-gel column chromatography (90% EtOAc/Hexane, Rt=0.25) to yield 4.3 g (45% yield) of ethyl 2-{4-[(4-{[4(4--chlorophenyl)pyrimin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetate: HPLC Retention time; 9.932 min. (Method B) M+1; 480.2

5  
2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetic Acid

To ethyl 2-{4-[(4-{[4(4--chlorophenyl)pyrimin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetate (5.0 g, 15.3 mmol) was added ethanol (69 mL) and NaOH (1.14 g, 29.2 mmol, 4.1 eq) in 46 mL water. The reaction was heated at 75°C for 1.5 hours. The reaction was acidified to pH=3, filtered, and dried, affording 4.3g of the acid 2-{4-[(4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetic acid (83.3%): HPLC Retention time; 9.260 min. (Method B) M+1; 452.3

15  
2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}N-ethylacetamide







2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetic acid (0.200 g, 0.44 mmol) was dissolved in DMF then stirred for 15 minutes in ice-brine solution, then the HOBT (0.072 g, 0.53 mmol) then EDCI(0.102 g, 0.53 mmol) were added and stirred for another 30 minutes. Ethylamine (0.030 mL, 0.53 mmol) was added and the reaction was left to stir at room temp overnight. The reaction was quenched with 10 mL of water and a precipitate formed. The precipitate was collected by filtration, and purified by preparative HPLC to yield 2-{4-[(4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}N-ethylacetamide: HPLC Retention time; 9.508 min.(Method B) M+1; 479.2




Compounds listed below were prepared according to the above procedure.

30


35



Compound Number	Structure	MW	RT, min	M+1
21-1		522.05	8.648	522.3
21-2		478.981	9.508	479.3
21-3		493.008	9.79	493.2
21-4		478.981	9.472	479.3
21-5		464.954	9.268	465.3
21-6		505.019	9.676	505.2

Compound Number	Structure	MW	RT, min	M+1
21-7		450.928	7.933	451.0
21-8		521.018 1	9.644	521.6
21-9		579.957	6.1	507.4

EXAMPLE 22  
REDUCTIVE AMINATION








20 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl} 4-[(methylethyl)amino]piperidyl ketone hydrochloride

25 1-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl}carbonyl]piperidin-4-one (400 mg, 0.980 mmol) was dissolved in 10 mL EtOH along with isopropylamine (58 mg, 0.980 mmol). Sodium cyanoborohydride (62 mg, 0.986 mmol) was added and the mixture was stirred at room temperature for 18 hours. The reaction was quenched with water, extracted with ethyl acetate followed by flash chromatography (EtOAc / MeOH; 90:10) to give a residue.

30 This was taken up in ETOH saturated with HCl(g), diluted with ether, filtered to give 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl} 4-[(methylethyl)amino]piperidyl ketone hydrochloride (0.150 g, 30 % yield): HPLC Retention time; 6.02 min. (Method B) M+1; 450.4.

Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
22-1		522.905	6.02	450.4
22-2		490.0478	10.612	490.3
22-3		465.9822	9.644	466.3
22-4		465.9822	9.604	466.3
22-5		465.9822	9.52	466.4

5







10

15



20

25

30

22-6		465.9822	9.584	466.4
22-7		480.009	9.604	480.2
22-8		519.0895	9.172	519.4
22-9		517.286	5.89	408.4
22-10		588.4076	5.43	479.4
22-11		451.9554	6.12	452.4

35

5	22-12		480.009	9.291	480.4
10	22-13		447.9674	9.976	448.4


20

25

30

35

EXAMPLE 23

SYNTHESIS OF REVERSE SULFONAMIDES

(2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one

A mixture of 4-nitroacetophenone (20.0 g, 121 mmol) and N,N-dimethylformamide dimethylacetal (200 ml) was refluxed for 18 hours, cooled and concentrated to give (2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one quantitatively.

5

1-Acetyl-4-[(4-{[4-(4-nitrophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazine

To a mixture of (2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one (250 mg, 1.14 mmol) and {4-{(4-acetyl)piperazinyl}carbonyl]phenyl}aminocarboxamidine (394 mg, 1.36 mmol) in methanol (6 ml) is added 2 mL of a 2.0M solution of sodium methoxide in methanol. The reaction mixture is then refluxed for 18 hours then acidified to pH ~ 4 using 1N HCl. The solid which formed at this time was then filtered and purified by column chromatography using 10% methanol in chloroform to give 320 mg (69%) of the desired product.

10

1-Acetyl-4-[(4-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazine

To a solution of 1-acetyl-4-[(4-{[4-(4-nitrophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazine (150 mg, 0.34 mmol) in methanol (5mL) containing a few drops of acetic acid, is added 100 mg of 10% Palladium-Charcoal. The solution is then hydrogenated at 50 psi for 6h at which time there remains no starting material. The solution is then filtered through a pad of Celite which gives 135 mg (95%) of essentially pure reduced material as a brown oil.

20

1-Acetyl-4-{[4-({4-[4-(phenylsulfonyl)aminophenyl]pyrimidin-2-yl}amino)phenyl]carbonyl}piperazine

25

To a solution of 1-acetyl-4-[(4-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazine (100 mg, 0.24 mmol) in pyridine (5 mL) containing a catalytic amount of DMAP is added benzenesulfonyl chloride (50 mg, 0.29 mmol) and the solution is stirred overnight at room temperature. The pyridine is removed under vacuum and the residue extracted into methylene chloride and washed with 1N HCl. Evaporation of solvent provides the crude piperazine which is purified by preparative HPLC (10-60% CH<sub>3</sub>CN over 25 min.) to give an analytically pure sample as a yellow solid: M+1; 557.3. HPLC Retention Time; 9.59 min (Method B).









30

35











Compounds listed below were prepared according to the above procedure.


Compound Number	Structure	MW	RT, min	M+1
23-1		586	8.03	587.3
23-2		624.6413	9.53	625.3
23-3		570.671	8.46	571.3

5	23-4		586.67	9	587.5
10	23-5		556.644	9.62	557.3
15	23-6		494.5734	8.35	495.3
20	23-7		591.0893	10.14	591.3
25	23-8		598.7246	10.25	599.5
30	23-9		624.6413	10.58	625.3
35	23-10		562.6724	9.56	563.3
	23-11		570.671	10.02	571.3

5	23-12		570.671	9.79	571.3
10	23-13		601.6413	7.15	602.5
15	23-14		601.6413	8.57	602.3
20	23-15		614.7236	8.23	615.5
25	23-16		514.6074	4.55	515.3
30	23-17		523.6151	8.85	524.3
35	23-18		586.67	9.72	587.3
	23-19		570.671	9.82	571.3





5	23-20		570.671	10.68	571.5
10	23-21		520.5902	9.89	521.3
15	23-22		535.6051	7.58	536.3
20	23-23		582.682	9.18	583.5
25	23-24		596.7088	9.76	597.5
30	23-25		637.7179	9.8	638.3





23-26		623.6911	9.2	624.5
23-27		528.6342	5.92	529.3





**EXAMPLE 24****SYNTHESIS OF FURTHER REPRESENTATIVE COMPOUNDS**

The compounds of Example 18, with the desired  $\text{R}_1$  moiety, may be modified according to the above procedures to yield further representative compounds of this invention.





For example, the following compounds were made according to the above procedures.





Compound Number	Structure	MW	RT, min	M+1
24-1		498.963	9.7	499
24-2		471.967	7.19	472
24-3		512.990	6.24	513
24-4		478.974	5.92	479





Compound Number	Structure	MW	RT, min	M+1
24-5		497.975	7.41	498
24-6		526.037	7.66	526
24-7		512.9985	8.350	513.4
24-8		478.9813	7.533	479.4





Compound Number	Structure	MW	RT, min	M+1
24-9		552.028	7.33	552.3
24-10		559.048	7.17	559.3
24-11		585.92	5.15	513.3
24-12		585.92	4.78	513












Compound Number	Structure	MW	RT, min	M+1
24-13		516.987	6.43	517.3
24-14		477.993	6.95	478.3
24-15		489.883	7.12	490.3
24-16		504.012	6.77	504.3






Compound Number	Structure	MW	RT, min	M+1
24-17		490.004	7.2	504.3
24-18		475.977	6.58	476.3
24-19		476.938	5.55	479.3
24-20		533.073	4.63	533.3






Compound Number	Structure	MW	RT, min	M+1
24-21		506.991	1.1	507.3
24-22		507.035	4.61	508.3
24-23		465.939	5.99	466.3
24-24		461.951	6.41	462.3

Compound Number	Structure	MW	RT, min	M+1
24-25		482.006	6.57	496.3
24-26		492.02	7.14	492.3
24-27		503.91	6.69	504.3
24-28		548.043	7.27	548.3

Compound Number	Structure	MW	RT, min	M+1
24-29		565.93	5.99	493.4
24-30		476.966	7.16	477.4
24-31		648.993	8.56	649.4
24-32		449.94	6.92	450.4

Compound Number	Structure	MW	RT, min	M+1
24-33		464.954	6.09	465.3
24-34		519.046	6.87	519.3
24-35		522.99	7.19	524.4
24-36		537.017	4.52	537.4
24-37		537.021	7.79	537.2


Compound Number	Structure	MW	RT, min	M+1
24-38		504.975	6.72	505.4
24-39		486.961	6.92	487.4
24-40		487.949	6.08	488.4
24-41		486.961	7.27	487.4
24-42		502.96	7.27	503.4

Compound Number	Structure	MW	RT, min	M+1
24-43		502.9597	7.27	503.4
24-44		533.0535	7.19	533.2
24-45		488.9329	7.09	489.4
24-46		588.4076	3.25	478.3
24-47		515.0143	7.16	515.4




EXAMPLE 25  
SYNTHESIS OF SULFIDES

5




10



15

20



25

30

3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone

35

To a stirred solution of 4-hydroxybutanethiol (5.0g, 47 mmol) in DMF (100 mL) was added NaH (60% dispersion in mineral oil, 2.1g). After the effervescence had ceased, *p*-chloroacetophenone (4.3 mL, 33 mmol) was added. The solution was then stirred at 110°C for 3 h. The mixture was cooled to RT and then diluted with ether (200 mL). The ethereal suspension was washed with 5% HCl (aq, 2 x 100 mL), water (100 mL), and then brine (50

mL). The ether extract was dried ( $\text{MgSO}_4$ ), filtered and concentrated to afford crude 1-[4-(4-hydroxybutylsulfanyl)phenyl]ethanone, which was used without purification. 1-[4-(4-hydroxybutylsulfanyl)phenyl]ethanone was taken up in dimethylformamide dimethylacetal (100 mL) and stirred at reflux for 12h. The mixture was cooled and then concentrated to about one half of the original volume. Hexane was added to precipitate 3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone. The mixture was filtered, washed with hexanes (50 mL), and dried to afford 3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone (6.4g, 23 mmol): HPLC Retention Time; 5.58 min. (Method B)  $M+1$ ; 279.8.

10 4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic Acid





3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)-phenyl]propenone (6.4g, 23 mmol) was, then taken up in *n*PrOH (150 mL). To this solution was added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 5.4 g) and  $\text{K}_2\text{CO}_3$  (3 equiv, 9.5 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted to pH 4-5 to 4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic acid. The acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (8.6 g, 21 mmol, 88%): HPLC Retention Time; 6.37 min. (Method B)  $M+1$ ; 396.0.






20




[4-(Furan-2-carbonyl)piperazin-1-yl]-4-{4-[4-(4-hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone





4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic acid (0.34 g, 0.86 mmol) was dissolved in THF (5 mL). To this solution was added 1-furoylpiperazine (0.170 g), EDCI (0.180 g), and HOBt (0.127 g). The mixture was stirred 12h. The mixture was then diluted with  $\text{CH}_2\text{Cl}_2$  (20 mL) and washed with 2% NaOH (aq, 30 mL), water (30 mL), and then brine (30 mL). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. The crude solid was subjected to preparatory HPLC (30 – 80 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with  $\text{CH}_2\text{Cl}_2$ /2% NaOH (aq). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated to afford [4-(Furan-2-carbonyl)-piperazin-1-yl]-4-{4-[4-(4-hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone (0.042 g, 9%): HPLC Retention Time; 10.07 min. (Method B)  $M + H = 558.3$ .





35 Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
25-1		557.672	10.07	558.3
25-2		505.64	9.26	506.3
25-3		562.735	8.81	563.3
25-4		500.064	8.37	464.4





5	25-5		571.699	12.04	572.3
10	25-6		519.667	11.13	520.3
15	25-7		576.762	10.24	577.2
25	25-8		514.091	9.7	478.3
30	25-9		529.618	9.5	530.3
35					

5	25-10		477.586	8.66	478.2
10	25-11		534.682	7.32	535.3
15	25-12		472.01	6.88	436.2





5	25-13		571.699	10.62	572.3
10	25-14		519.667	9.76	520.2
15	25-15		477.63	8.77	478.3
20	25-16		491.657	8.9	492.3
25					
30					

5	25-17		576.762	9.25	577.3
10	25-18		492.641	9.59	493.3
15	25-19		562.779	8.42	563.3
20	25-20		588.773	8.51	589.3


35

5	25-21		571.699	10.85	572.3
10	25-22		519.667	10.05	520.3
15	25-23		477.63	9	478.3
20	25-24		576.762	9.46	577.3
25					
30					
35					



25-25		491.657	9.1	492.3
25-26		562.779	8.58	563.3
25-27		588.773	9.39	589.5
25-28		492.641	9.84	493.3

EXAMPLE 26  
SYNTHESIS OF SULFONAMIDES



30 1-[4-(Morpholine-4-sulfonyl)phenyl]ethanone

To a suspension of 4-acetylbenzenesulfonyl chloride (5.5 g, 25 mmol) in  $\text{CH}_2\text{Cl}_2$  (75 mL) and  $\text{Et}_3\text{N}$  (2 equiv, 7.0 mL, 50 mmol) was added morpholine (1.5 equiv, 3.3 mL, 38 mmol) dropwise. The mixture was stirred at room temperature for 30 min. The mixture was then diluted with  $\text{CH}_2\text{Cl}_2$  (100 mL) and washed with 5%  $\text{HCl}$  (2 x 50 mL), water (50 mL), and  
 35 then brine (50 mL). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated to afford

crude 1-[4-(morpholine-4-sulfonyl)phenyl]ethanone (2) (4.78g, 18 mmol, 71%): HPLC Retention Time; 5.82 min. (Method B) M+1, 270.0.

4-{4-[4-(Morpholine-4-sulfonyl)-phenyl]-pyrimidin-2-ylamino}benzoic Acid




5                   Crude 1-[4-(morpholine-4-sulfonyl)phenyl]ethanone (4.78g, 18 mmol) was suspended in dimethylformamide dimethylacetal (50 mL) and refluxed for 12 h. The reaction was allowed to cool and the mixture was concentrated to about half of the original volume. The solution was then titrated with hexanes to precipitate the eneamino ketone intermediate. The eneamino ketone was filtered and washed with hexanes (2 x 50 mL), dried under vacuum, and  
10 then taken up in *n*PrOH (150 mL). To this solution was added added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 3.7 g) and K<sub>2</sub>CO<sub>3</sub> (3 equiv, 6.4 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted to pH 4-5 to  
15 precipitate the acid. 4-{4-[4-(morpholine-4-sulfonyl)phenyl]pyrimidin-2-ylamino}benzoic acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (4.6 g, 10.5 mmol, 68%): HPLC Retention Time; 6.6 min. (Method B) M+1, 441.0.





20 [4-(Furan-2-carbonyl)-piperazin-1-yl](4-{4-[4-(morpholine-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone





                  4-{4-[4-(Morpholine-4-sulfonyl)-phenyl]-pyrimidin-2-ylamino}-benzoic acid (0.25 g, 0.57 mmol) was dissolved in THF (5 mL). To this solution was added 1-furoylpiperazine (0.123 g), EDCI (0.131 g), and HOBt (0.092 g). The mixture was stirred 12h. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and washed with 2% NaOH (aq, 30 mL),  
25 water (30 mL), and then brine (30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude solid was subjected to preparatory HPLC (20 – 70 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>/2% NaOH (aq). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford [4-(furan-2-carbonyl)piperazin-1-yl](4-  
30 {4-[4-(morpholine-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}phenyl)methanone (0.177 g, 52%): HPLC Retention Time; 9.62 min. (Method B)  
M + H = 603.3





35





Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
26-1		602.669	9.62	603.3
26-2		550.637	8.88	551.3
26-3		508.6	7.6	509.3

26-4		607.732	8.34	608.3
26-5		522.627	7.9	523.3
26-6		593.749	6.33	594.3
26-7		619.743	8.28	620.3

5	26-8		523.611	8.76	524.3
10	26-9		576.718	8.21	577.3
15	26-10		576.675	10.26	577.3
20	26-11		592.717	12.12	593.3
25					
30					





26-12		564.664	10.04	565.3
26-13		578.691	10.51	579.3
26-14		631.711	10.33	632.4
26-15		466.563	10.4	467.3





5	26-16		508.6	11.35	509.3
10	26-17		560.632	12	561.3
15	26-18		616.696	9.72	617.3
20	26-19		564.664	8.93	565.5

30

35



26-20		522.627	7.99	523.3
26-21		590.745	8.34	591.3
26-22		563.6797	8.05	564.3
26-23		591.6897	9.01	592.3

5	26-24		619.7433	9.25	620.3
10	26-25		548.6648	10.88	549.5
15	26-26		534.638	10	535.3
20	26-27		552.6528	6.82	553.3

30

35

5





10

15





20






25





30






26-28		522.627	10.18	523.3
26-29		617.7711	8.31	618.5
26-30		556.6442	10.29	557.2
26-31		494.5734	8.96	495.3






35

5	26-32		562.6916	11.36	563.4
10	26-33		562.6916	11.2	563.4
15	26-34		562.6916	11.52	563.4
20	26-35		562.6916	11.5	563.4




5	26-36		564.6638	9.14	565.4
10	26-37		549.6529	8.04	550.4
15	26-38		565.6519	8.26	566.3
20	26-39		538.626	9.14	539.3
25	26-40		551.6687	7.77	552.3







5	26-41		506.628	9.64	507.4
10	26-42		492.6012	9.08	493.4
15	26-43		534.6816	9.9	535.3
20	26-44		591.7769	9.16	592.5








26-45		578.7342	10.25	579.5
26-46		520.6548	9.32	521.5
26-47		564.7074	9.7	565.5
26-48		577.7501	8.66	578.5
26-49		563.7233	8.77	564.5

5	26-50		577.7501	9.28	578.5
10	26-51		536.6538	8.89	537.5
15	26-52		580.7064	9.29	581.4
20	26-53		579.7223	8.4	580.5
25	26-54		538.6629	9.44	539.3
30					
35					






26-55		494.617	9.06	495.3
26-56		537.6855	8.56	538.5
26-57		551.7123	8.47	552.5

5	26-58		536.6538	10.64	537
10	26-59		570.671	10.63	571
15	26-60		576.7184	11.43	577
20	26-61		596.7054	10.01	597
25	26-62		550.6806	11.75	551
30	26-63		564.7074	11.82	565

5	26-64		571.6591	8.11	572
	26-65		536.6538	10.28	537
10	26-66		536.6538	10.24	537
15	26-67		579.6787	8.71	580
20	26-68		591.0893	11.07	591
25	26-69		562.6916	10.9	563
30	26-70		560.6322	10.74	561

EXAMPLE 27  
SYNTHESIS OF SULFONES



30

1-[4-(Tetrahydropyran-4-sulfanyl)phenyl]ethanone

To a stirred solution of  $\text{Na}_2\text{S}$  (17.4 g, 0.22 mol) in water (26 mL) was added  $\text{CS}_2$  (14.7 mL, 0.24 mol). The mixture was stirred at 60 – 70°C for 6h. To the resultant red solution of  $\text{Na}_2\text{CS}_3$  was added 4-chlorotetrahydropyran (0.074 mol). The mixture was stirred for 12h at 60 – 70°C. The mixture was then cooled to ~10°C.  $\text{H}_2\text{SO}_4$  (conc.) was

35

added to the mixture dropwise with stirring until a cloudy yellow color persisted. The mixture was then extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 50 mL). The aqueous layer was discarded and the  $\text{CH}_2\text{Cl}_2$  layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. The crude thiol (47.5 mmol, ~64%) was dissolved in DMF (100 mL) and treated with NaH (1.9g, 48 mmol).  
5 After the effervescence had ceased, *p*-chloroacetophenone (4.3 mL, 33 mmol) was added. The solution was then stirred at 110°C for 3 h. The mixture was cooled to RT and then diluted with ether (200 mL). The ethereal suspension was washed with 5% HCl (aq, 2 x 100 mL), water (100 mL), and then brine (50 mL). The ether extract was dried ( $\text{MgSO}_4$ ), filtered and concentrated to afford crude 1-[4-(tetrahydro-pyran-4-sulfanyl)-phenyl]-  
10 ethanone 1, which was purified by chromatography ( $\text{SiO}_2$ , 9:1 hex/EtOAc) to afford pure 1-[4-(tetrahydropyran-4-sulfanyl)phenyl]ethanone 1 (7.4 mmol, 16% from 4-chlorotetrahydropyran): HPLC Retention Time; 5.41 min. (Method B) M+1; 269.0.

3-Dimethylamino-1-[4-(tetrahydropyran-4-sulfonyl)phenyl]propenone

15 1-[4-(Tetrahydro-pyran-4-sulfanyl)-phenyl]-ethanone 1 (7.4 mmol) was dissolved in acetone/water (9:1 v/v, 100 mL). Oxone® (2.1 equiv, 9.1 g) was added to the solution. The reaction was stirred at room temperature for 5h. The mixture was filtered and the majority of acetone was removed *in vacuo*. The solution was then diluted with water (50 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 50 mL). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ),  
20 filtered, and concentrated to afford the intermediate tetrahydropyranyl sulfone, which was taken up in dimethylformamide dimethylacetal (100 mL) and stirred at reflux for 12h. The mixture was cooled and then concentrated to about one half of the original volume. Hexane was added to precipitate eneamino ketone intermediate. The mixture was filtered, washed with hexanes (50 mL), and dried to afford 3-dimethylamino-1-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-propenone (2.2g, 7 mmol): HPLC Retention Time; 5.18 min. (Method B)  
25 M+1; 324.0.

4-{4-[4-(Tetrahydropyran-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}benzoic Acid


30 3-Dimethylamino-1-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-propenone was then taken up in *n*PrOH (80 mL). To this solution was added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 1.7 g) and  $\text{K}_2\text{CO}_3$  (3 equiv, 2.9 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted  
35 to pH 4-5 to precipitate 4-{4-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-pyrimidin-2-

ylamino}-benzoic acid 4. The acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (2.4 g, 5.5 mmol, 79% yield): HPLC Retention Time; 6.07 min. (Method B) M+1; 593.3.

5 [4-(3-Dimethylamino-propyl)-piperazin-1-yl]-(4-{4-[4-(tetrahydropyran-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone

4-{4-[4-(Tetrahydropyran-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}benzoic acid 4 (0.26 g, 0.6 mmol) was dissolved in THF (5 mL). To this solution was added 1-(N,N-dimethylaminopropyl)piperazine (0.130 g), EDCI (0.136 g), and HOBt (0.096 g). The mixture was stirred 12h. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and washed with 2% NaOH (aq, 30 mL), water (30 mL), and then brine (30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude solid was subjected to preparative HPLC (20 – 70 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>/2% NaOH (aq). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford [4-(3-dimethylamino-propyl)piperazin-1-yl]-(4-{4-[4-(tetrahydropyran-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone 5 (0.079 g, 22%): HPLC Retention Time; 7.93 min. (Method B) M + 1 = 593.3

20 Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
27-1		612.664	10.25	595.3

5

10





15





20

25





30




35

27-2		542.617	8.7	543.3
27-3		515.591	8.57	516.3
27-4		623.6911	9.36	624.3
27-4		601.681	10.06	602.4

5	27-5		606.744	8.64	607.4
10	27-6		507.612	8.37	508.3
15	27-7		521.639	8.57	522.3
20	27-8		592.761	7.93	593.3
25					
30					










5	27-9		575.73	8.57	576.3
10	27-10		522.623	8.95	523.3
15	27-11		630.723	10.25	631.3
20	27-12		549.649	9.5	550

5	27-13		500.5806	8.8	501.3
10	27-14		571.699	9.78	572.3
15	27-15		583.71	9.736	584.5
20					
25					

30

35

27-16		541.629	10.484	542.3
27-17		593.661	11.264	594.3
27-18		513.619	9.336	514.3
27-19	 ClH ClH	572.514	9.204	500

5	27-20		584.741	8.692	585.2
10	27-21		528.63	10.648	529.2
15	27-22		458.54	11.44	458.9
20					
25					

EXAMPLE 28

## ACTIVITY OF REPRESENTATIVE COMPOUNDS

30 The compounds of this invention may be assayed for IKK-2 inhibitory activity according to the following procedures.

IKK-2 ENZYME ASSAY

35 To 10  $\mu$ l of the test compound in 20% DMSO in "Dilution Buffer" (20 mM HEPES pH 7.6, 0.1 mM EDTA, 2.5 mM  $MgCl_2$ , 0.004% Triton X100, 2  $\mu$ g/ml Leupeptin, 20 mM  $\beta$ -glycero-phosphate, 0.1 mM  $Na_3VO_4$ , 2 mM DTT) is added 30  $\mu$ l of 167  $\mu$ g/ml

GST-I $\kappa$ B $\alpha$  in "HBB" (20 mM HEPES pH 7.6, 50 mM NaCl, 0.1 mM EDTA, 2.5 mM MgCl<sub>2</sub>, 0.05% Triton X100) and 30  $\mu$ l IKK2EE(his<sub>6</sub>) at 1.33  $\mu$ g/ml (40 ng/well). The mixture is preincubated for 15 minutes at room temperature. Then 30  $\mu$ l of "Kinase Buffer" (20 mM HEPES pH 7.6, 6.67 mM MgCl<sub>2</sub>, 6.67 mM MnCl<sub>2</sub>, 0.02% Triton X100, 20 mM  $\beta$ -glycerolphosphate, 2 mM NaF, 2 mM DTT, 2 mM benzamidine, 16 mM para-nitrophenylphosphate, 5  $\mu$ M ATP, 16.67  $\mu$ Ci/ml  $\gamma$ <sup>33</sup>P-ATP) is added and the reaction is allowed to proceed for 1 hour at room temperature. The I $\kappa$ B $\alpha$  is precipitated and phosphorylation terminated by addition of 150  $\mu$ l 12.5% trichloroacetic acid. After 30 minutes the precipitate is harvested onto a filter plate to which 50  $\mu$ l of scintillation fluid is added and then quantified by a scintillation counter. The IC<sub>50</sub> values are calculated as the extrapolated concentration of the test compound at which the I $\kappa$ B $\alpha$  phosphorylation was reduced to 50% of the control value.

#### Detection of I $\kappa$ B $\alpha$ Degradation

Human umbilical vein endothelial cells (HUVEC) are cultured to 80% confluency and then pre-treated with compound (30  $\mu$ M) at a final concentration of 0.5% DMSO. After 30 minutes, cells are stimulated with TNF $\alpha$  (30 ng/ml) for 20 minutes. Cells are washed, scraped from the plate, lysed with 2x Laemmli buffer and heated to 100°C for 5 minutes. Whole cell lysate (approx. 30  $\mu$ g) is fractionated on Tris-glycine buffered 10% SDS-polyacrylamide gels (Novex, San Diego, CA) and transferred to nitrocellulose membrane (Amersham, Piscataway, NJ). Membranes are blocked with 5% non-fat milk powder (BioRad, Hercules, CA) and incubated with antibody to I $\kappa$ B $\alpha$  (0.2  $\mu$ g/ml #sc-371) (Santa Cruz Biotechnology, Santa Cruz, CA) and then donkey anti-rabbit horse radish peroxidase conjugated antibody (1:2500) (Amersham) in phosphate buffered saline with 0.1% Tween-20 and 5% non-fat milk powder. Immunoreactive proteins are detected with chemiluminescence and autoradiography (Amersham).

#### Inhibition of Cell Adhesion Molecule Expression

Enzyme Linked Immunosorbent Assay (ELISA) to determine endothelial cell adhesion molecule expression is performed as described by (Bennett et al., *J. Biol Chem.* 272:10212-12219, 1997). Briefly, HUVEC are plated in 96 well microtiter plates and grown to confluence. Cells are pre-treated with compound (30  $\mu$ M) at a final concentration of 0.5% DMSO. After 30 minutes, cells are stimulated with TNF $\alpha$  (30 ng/ml) for 5 hours. Following experimental treatment, cells are washed once with phosphate buffered saline (PBS) and incubated with freshly prepared 4% paraformaldehyde solution, pH 7, for 60 min.

Plates are then washed once with PBS, blocked overnight at 4°C with 2% bovine serum albumin (BSA) in PBS, washed once with PBS and incubated with 1 µg/ml primary antibody in 0.1% BSA in PBS at 37°C for 2 hours. Monoclonal antibodies used are to E-selectin (BBA16; R&D Systems, Minneapolis, MN), VCAM-1 (MA10620; Endogen, Woburn, MA), ICAM-1 (BBA3; R&D Systems), and ICAM-2 (AHT0201; Biosource, Camarillo, CA). After incubation with primary antibody, the cells are washed three times with 0.05% Tween-20 in PBS, incubated with alkaline phosphatase-conjugated goat anti-mouse IgG (AMI3405; Biosource) in 0.1% BSA in PBS at 37°C for 1 hour, washed three times with 0.05% Tween-20 in PBS and once with PBS. The cells are then incubated in chromogenic substrate (1 mg/ml p-nitrophenyl phosphate in 1 M diethanolamine, 0.5 mM MgCl<sub>2</sub>, pH 9.8) at 37°C for 30 min and absorbance measured at 405 nm using a ThermoMax microplate reader (Molecular Devices, Menlo Park, CA).

#### Rat *in vivo* LPS-induced TNF-α Production Assay

Male CD rats procured from Charles River Laboratories at 7 weeks of age are allowed to acclimate for one week prior to use. A lateral tail vein is cannulated percutaneously with a 22-gauge over-the-needle catheter under brief isoflurane anesthesia. Rats are administered test compound either by intravenous injection via the tail vein catheter or oral gavage 15 to 180 min prior to injection of 0.05 mg/kg LPS (E. Coli 055:B5). Catheters are flushed with 2.5 mL/kg of normal injectable saline. Blood is collected via cardiac puncture 90 minutes After LPS challenge. Plasma is prepared using lithium heparin separation tubes and frozen at -80 °C until analyzed. TNF-α levels are determined using a rat specific TNF-α ELISA kit (Biosource). The ED<sub>50</sub> values are calculated as the dose of the test compound at which the TNF-α production is reduced to 50% of the control value. Preferred compounds of the present invention have an ED<sub>50</sub> value ranging 1-30 mg/kg in this assay.

#### EXAMPLE 29

##### ACTIVITY OF REPRESENTATIVE COMPOUNDS

Representative compounds of this invention may be assayed for their ability to inhibit IKK-2 by the assays set forth in Example 21. In this regard, preferred compounds of this invention have an IC<sub>50</sub> value in the IKK-2 Enzyme Assay of Example 21 of 1 µM or less. To this end, preferred compounds of this invention are 1, 3-8, 3-9, 3-13, 3-14, 3-15, 3-21, 3-34, 17-2, 17-3, 17-18, 17-20, 17-21, 17-22, 17-23, 17-25, 17-27, 17-28, 17-29, 17-30, 17-31, 17-32, 17-33, 17-34, 17-35, 17-36, 17-54, 17-71, 17-72, 17-86, 17-91, 17-118, 17-

127, 17-128, 17-129, 17-131, 17-132, 17-133, 17-136, 17-137, 17-139, 17-141, 17-142, 17-144, 17-147, 17-150, 17-151, 17-152, 17-153, 17-154, 17-158, 17-159, 17-160, 17-161, 17-162, 17-163, 17-169, 17-171, 17-190, 17-215, 18, 20-1, 20-2, 20-3, 20-4, 20-5, 20-6, 22-10, 22-11, 25-52. More preferably, compounds of this invention have IC<sub>50</sub> value in the IKK-2  
5 Enzyme Assay of Example 21 of 500 nM or less. In this regard, more preferred compounds of this invention are 3-8, 3-14, 3-21, 17-18, 17-2, 17-20, 17-27, 17-28, 17-29, 17-30, 17-31, 17-32, 17-33, 17-34, 17-35, 17-36, 17-37, 17-86, 17-91, 17-127, 17-129, 17-131, 17-133, 17-137, 17-139, 17-141, 17-150, 17-154, 17-159, 17-160, 17-161, 17-162, 17-163, 17-169, 17-171, 17-190, 17-215, 18, 20-1, 20-2, 20-3, 20-4, 20-5, 20-6, 22-10, 22-11, 25-52.

10

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those  
15 shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims.

20

25


30

35

What is claimed is:

1. A compound having the structure:

5



10 or a pharmaceutically acceptable salt thereof,

wherein:

$R_1$  is aryl or heteroaryl optionally substituted with one to four substituents independently selected from  $R_7$ ;

$R_2$  is hydrogen;

15

$R_3$  is hydrogen or lower alkyl;

$R_4$  represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;

20

$R_5$  and  $R_6$  are the same or different and independently  $-R_8$ ,  $-(CH_2)_aC(=O)R_9$ ,  $-(CH_2)_aC(=O)OR_9$ ,  $-(CH_2)_aC(=O)NR_9R_{10}$ ,  $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$ ,  $-(CH_2)_aNR_9C(=O)R_{10}$ ,  $-(CH_2)_aNR_{11}C(=O)NR_9R_{10}$ ,  $-(CH_2)_aNR_9R_{10}$ ,  $-(CH_2)_aOR_9$ ,  $-(CH_2)_aSO_2R_9$ , or  $-(CH_2)_aSO_2NR_9R_{10}$ ;

25

or  $R_5$  and  $R_6$  taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

30

$R_7$  is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-OC(=O)R_8$ ,  $-C(=O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2R_8$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

35

$R_8$ ,  $R_9$ ,  $R_{10}$ , and  $R_{11}$  are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted



aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl; or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;  
5  $a$  and  $b$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and  
 $c$  is at each occurrence 0, 1 or 2.

10 2. The compound of claim 1 wherein  $R_5$  and  $R_6$ , taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle.

15 3. The compound of claim 2 wherein the nitrogen-containing non-aromatic heterocycle is morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, hydantoinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, oxazolidinyl, thiazolidinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.

20 4. The compound of claim 1 wherein  $R_1$  is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not pyridyl.

25 5. The compound of claim 1 wherein  $R_1$  is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.

30 6. The compound of claim 1 wherein  $R_1$  is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl.

7. The compound of claim 1 wherein  $R_1$  is aryl.


35 8. The compound of claim 3 the nitrogen-containing non-aromatic heterocycle is piperazinyl.

9. The compound of claim 3 the nitrogen-containing non-aromatic heterocycle is piperidinyl.

10. The compound of claim 3 the nitrogen-containing non-aromatic heterocycle is morpholinyl.

11. A composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier.

12. A method for treating a condition responsive to IKK-2 inhibition, comprising administering to a patient in need thereof and effective amount of a compound having the structure:



or a pharmaceutically acceptable salt thereof,

wherein:

R<sub>1</sub> is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R<sub>7</sub>;

R<sub>2</sub> and R<sub>3</sub> are the same or different and are independently hydrogen or lower alkyl;

R<sub>4</sub> represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

R<sub>5</sub> and R<sub>6</sub> are the same or different and independently -R<sub>8</sub>, -(CH<sub>2</sub>)<sub>a</sub>C(=O)R<sub>9</sub>,  
 -(CH<sub>2</sub>)<sub>a</sub>C(=O)OR<sub>9</sub>, -(CH<sub>2</sub>)<sub>a</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>,  
 -(CH<sub>2</sub>)<sub>a</sub>C(=O)NR<sub>9</sub>(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>NR<sub>9</sub>C(=O)R<sub>10</sub>,  
 -(CH<sub>2</sub>)<sub>a</sub>NR<sub>11</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>OR<sub>9</sub>,  
 -(CH<sub>2</sub>)<sub>a</sub>SO<sub>c</sub>R<sub>9</sub>, or -(CH<sub>2</sub>)<sub>a</sub>SO<sub>2</sub>NR<sub>9</sub>R<sub>10</sub>;

or R<sub>5</sub> and R<sub>6</sub> taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R<sub>7</sub> is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl,

sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-OC(=O)R_8$ ,  $-C(=O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2R_8$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl; or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;  $a$  and  $b$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and  $c$  is at each occurrence 0, 1 or 2.

13. The method of claim 12 wherein the condition is an inflammatory or autoimmune condition.

14. The method of claim 13 wherein the inflammatory or autoimmune condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus.

15. The method of claim 12 wherein the condition is a cardiovascular, metabolic or ischemic condition.

16. The method of claim 15 wherein the condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, Type II diabetes, osteoporosis, erectile dysfunction, cachexia, myocardial infarction, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, or multiple organ failure.

17. The method of claim 12 wherein the condition is an infectious disease.
18. The method of claim 17 wherein the infectious disease is a viral infection.
19. The method of claim 18 wherein the viral infection is caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, human T-cell leukemia virus or Epstein-Barr virus.
20. The method of claim 12 wherein the condition is cancer.
21. The method of claim 20 wherein the cancer is of the colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, testes, urinary bladder, ovary or uterus.
22. The method of claim 12 wherein the condition is stroke, epilepsy, Alzheimer's disease, or Parkinson's disease.
23. The method of claim 20 further comprising administering an effective amount of a cytotoxic agent or radiation therapy.
24. A method for treating an inflammatory or an autoimmune condition comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1.
25. The method of claim 24 further comprising administering an effective amount of an anti-inflammatory agent.
26. The method of claim 25, wherein the anti-inflammatory agent is salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, piroxicam, tenoxicam, nabumetone, phenylbutazone,

oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, colchicine, allopurinol, probenecid, sulfinpyrazone, benzbromarone, enbrel, infliximab, anakinra, celecoxib or rofecoxib.

5                   27.     The method of claim 24, wherein the inflammatory or autoimmune condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, 10 dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus.

                  28.     A method for treating a cardiovascular, metabolic or ischemic condition comprising administering to a patient in need thereof an effective amount of a 15 compound or pharmaceutically acceptable salt of the compound of claim 1.

                  29.     The method of claim 28, wherein the condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, Type II diabetes, osteoporosis, erectile dysfunction, cachexia, myocardial infraction, ischemic diseases of 20 heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, or multiple organ failure.

                  30.     A method for treating an infectious disease comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically 25 acceptable salt of the compound of claim 1.

                  31.     The method of claim 30 wherein the infectious disease is a viral infection.

30                   32.     The method of claim 31 wherein the viral infection is caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, human T-cell leukemia virus or Epstein-Barr virus.

                  33.     A method for treating cancer comprising administering to a patient in 35 need thereof an effective amount of a compound or pharmaceutically acceptable salt of the

compound of claim 1.

34. The method of claim 33 further comprising administering an effective amount of an anti-cancer agent.

5

35. The method of claim 34 wherein the anti-cancer agent is cyclophosphamide, Ifosfamide, trofosfamide, Chlorambucil, carmustine (BCNU), Lomustine (CCNU), busulfan, Treosulfan, Dacarbazine, Cisplatin, carboplatin, vincristine, Vinblastine, Vindesine, Vinorelbine, paclitaxel, Docetaxol, etoposide, Teniposide, 10 Topotecan, 9-aminocamptothecin, camptothecin, crizotinib, mytomicin C, methotrexate, Trimetrexate, mycophenolic acid, Tiazofurin, Ribavirin, EICAR, hydroxyurea, deferoxamine, 5-fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, cytarabine (ara C), cytosine arabinoside, fludarabine, mercaptopurine, thioguanine, Tamoxifen, Raloxifene, megestrol, goserelin, Leuprolide acetate, flutamide, bicalutamide, B 1089, CB 1093, KH 15 1060, vertoporphin (BPD-MA), Phthalocyanine, photosensitizer Pc4, demethoxyhypocrellin A (2BA-2-DMHA), interferon- $\alpha$ , interferon- $\gamma$ , tumor-necrosis factor, Lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, Actinomycin D, Dactinomycin, bleomycin A2, Bleomycin B2, Peplomycin, daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, Mitoxantrone, verapamil or thapsigargin.

20

36. The method of claim 33 wherein the cancer is of the colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, testes, urinary bladder, ovary or uterus.

25

37. A method for treating stroke, epilepsy, Alzheimer's disease, or Parkinson's disease comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1.

30

38. The compound of claim 7 wherein aryl is phenyl.

35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 June 2002 (13.06.2002)

PCT


(10) International Publication Number  
WO 02/046171 A3

- (51) International Patent Classification<sup>7</sup>: C07D 239/42, 401/12, 405/12, 413/12, 403/12, A61K 31/505, A61P 29/00
- (74) Agents: INSOGNA, Anthony, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US01/46403
- (22) International Filing Date: 5 December 2001 (05.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/251,816 6 December 2000 (06.12.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: SIGNAL PHARMACEUTICALS, INC. [US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US).
- (72) Inventors: KOIS, Adam; 11363 Redbud Court, San Diego, CA 92127 (US). MACFARLANE, Karen, J.; 11435 Belshire Lane, San Diego, CA 92126 (US). SATOH, Yoshitaka; 11460 Larmier Circle, San Diego, CA 92131 (US). BHAGWAT, Shripad, S.; 5015 Ashley Falls Court, San Diego, CA 92130 (US). PARNES, Jason, S.; 12511 El Camino Real #C, San Diego, CA 92139 (US). PALANKI, Moorthy, S., S.; 602 Crest Drive, Encinitas, CA 92024 (US). ERDMAN, Paul, E.; 8225 Jade Coast #93, San Diego, CA 92126 (US).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
23 January 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/046171 A3

(54) Title: ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO



(57) Abstract: Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilino-pyrimidine derivatives having the following structure: (A) wherein R<sub>1</sub> and R<sub>6</sub> are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/46403

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/42 C07D401/12 C07D405/12 C07D413/12 C07D403/12  
A61K31/505 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 01439 A (DU PONT) 14 January 1999 (1999-01-14) page 0; claims; example 22 ----	1, 11, 38
E	WO 02 46170 A (SIGNAL) 13 June 2002 (2002-06-13) the whole document -----	1-38

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

10 July 2002

Date of mailing of the international search report

17/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 01/46403

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 12 to 37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/46403

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9901439	A	14-01-1999	AU 8181098 A	25-01-1999
			EP 0994860 A1	26-04-2000
			JP 2002510322 T	02-04-2002
			WO 9901439 A1	14-01-1999
			US 6103737 A	15-08-2000
WO 0246170	A	13-06-2002	WO 0246170 A2	13-06-2002